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ABSTRACT 
 
 Heart disease and diabetes mellitus are growing epidemics, consistently ranking within 
the top ten causes of death in the United States.  Both diseases are associated with cardiac 
remodeling, including cellular growth and fibrosis.  Central to the progression of heart disease 
and diabetes are the adrenergic receptors (ARs) and insulin receptors (IR), respectively.  
Classically considered to elicit separate, and even opposing, cellular processes, increasing 
evidence suggests that ARs are capable of signaling cross-talk with other G-protein coupled 
receptors (GPCRs) as well as other receptor families, including receptor tyrosine kinases 
(RTKs).  While the ARs have been implicated at numerous stages of heart failure, the adrenergic 
signaling mechanisms underlying this remodeling remain unknown.  Further, studies 
investigating signaling cross-talk among different adrenergic receptors as well as between 
adrenergic receptors and other signaling pathways in myocardium remain in their infancy.  In 
addition, few studies have implied functional interactions between IRs and βARs in cardiac 
tissues.  Understanding how cells integrate information from a variety of chemically diverse 
signals into complex, orchestrated responses such as cell proliferation, differentiation and 
apoptosis is an overarching goal of cell biology.  Thus, an understanding of the mechanisms and 
physiologic consequences of adrenergic receptor cross-talk within the heart is essential to 
develop novel treatments designed to prevent the cardiac remodeling observed in heart disease 
and diabetes.  In concordance, the goals of this thesis research are two-fold.  First, we aim to 
define mechanisms of AR cross-talk in cardiac cells.  Secondly, we aim to determine the 
importance of these mechanisms in cardiac remodeling in response to pathological conditions.       
  To begin to address the goals presented we first examined cross-talk within GPCRs.  We 
elucidated a general mechanism in which non-traditional GPCR signaling is capable of 
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regulating mitogen-activated protein kinase (MAPK) signaling originating from another GPCR.  
Interestingly, this cross-talk impaired GPCR-induced cellular proliferation.  Next, we 
characterized a novel signaling mechanism in which type II RTK activation at high 
concentrations of mitogen can recruit non-traditional GPCR signaling components to fine-tune 
activation of MAPK signaling for cell proliferation.  In sum, this work presents a significant 
expansion of our understanding of GPCR signaling cross-talk and its role in altering growth 
signaling originating from another receptor.  Further, due to the complexities of hormonal 
signaling in vivo, this work highlights the need to further pursue a more in-depth understanding 
of how concomitant activation of one signaling pathway can alter the signaling and physiologic 
outcome of another receptor’s signaling.  
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Chapter 1: 
Cardiac remodeling and the receptor signaling pathways implicated in its 
pathogenesis 
 
Cardiovascular disease consistently remains the leading cause of morbidity and mortality 
in the United States, leading to nearly 30% of deaths in 2006.  In addition to the human impact, 
the economic impact of cardiovascular disease is staggering with an estimated 503.2 billion 
dollars spent in 2010.  Chronic diseases specifically affecting the heart, including heart failure, 
account for a significant portion of that impact (www.americanheart.org).  Because heart failure 
increases the risk of sudden cardiac death six to nine times that of the general population, an 
understanding of the physiological and pathophysiological process of remodeling in the heart 
remains an important area of investigation.  While the adrenergic receptors have been implicated 
at numerous stages of heart failure, the adrenergic signaling mechanisms underlying this 
remodeling remain unknown.  Further, studies investigating signaling cross-talk among different 
adrenergic receptors as well as between adrenergic receptors and other signaling pathways in 
myocardium remain in their infancy.  Importantly, no study has investigated the role of 
adrenergic receptor cross-talk in both physiological and pathological processes.  Thus, the goals 
of this thesis research are two-fold.  First, we aim to define mechanisms of receptor cross-talk in 
cardiac cells.  Secondly, we aim to determine the importance of these mechanisms in cardiac 
remodeling in response to pathological conditions.  
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Cardiac remodeling and heart failure 
Cardiac hypertrophy is an essential adaptive cardiac response initially serving as a 
compensatory response to increased work demand(1, 2).  This initial compensatory mechanism is 
the main indication for heart failure.  Heart failure is the result of a well-characterized sequence 
of cardiac remodeling resulting from numerous environmental (hypertension, diabetes, ischemia) 
and genetic factors (congenital heart failure) (Fig 1.1).  Hypertension, the leading risk factor for 
cardiovascular disease and heart failure, prevents efficient functioning of the heart and increases 
the preload of the left ventricle(3).  Increased preload in the left ventricle, along with elevated 
circulating catecholamines, leads to a compensatory increase in contraction strength via cardiac 
myocyte hypertrophy.  This initial compensatory concentric cardiac hypertrophy is the leading 
indication for decompensated eccentric heart failure(4).  Increased thickness of the myocardium 
along with increased metabolic demand on the heart leads to endocardial ischemia and cardiac 
myocyte death.  In an attempt to repair the damaged cardiac muscle, fibroblasts proliferate and 
secrete collagen, leading to cardiac fibrosis.  Decreased myocardial mass, in addition to fibrosis, 
exaggerates the loss of cardiac contractile function leading to cardiac insufficiency; it also 
enhances cardiac arrhythmia and sudden cardiac death. 
Although the mechanisms are unknown, cardiac remodeling and heart failure have been 
linked to chronic activation of the adrenergic receptors due to elevated circulating 
catecholamines(1). While the functional integrity of adrenergic signaling is critical in maintaining 
cardiac output for physiological responses, decreased cardiac response to adrenergic stimulation 
is linked to the development of heart failure(5).  Further, adrenergic manipulation remains a 
leading treatment for hypertension and heart failure.   
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Diabetes and heart failure 
 Diabetes Mellitus is a growing epidemic, affecting nearly 24 million people, or nearly 8% 
of the population, in the United States.  The human and economic cost of diabetes mellitus, the 
sixth leading killer in the United States, is enormous with direct diabetic care expenses totaling 
$116 billion dollars in 2007(6, 7).  Type 2 diabetes mellitus, accounting for 90-95% of diabetes 
cases, is a well known risk factor for cardiomyopathy and eventual heart failure (HF)(8, 9).  
Diabetic cardiomyopathy (DCM) is characterized by both systolic and diastolic dysfunction 
resulting from aberrant contractility as well as cardiac hypertrophy, in the absence of coronary 
artery disease (CAD) and hypertension(10).  Interestingly, DCM is associated with 
hyperinsulinemia and depressed adrenergic signaling leading to decreased contractility despite 
elevated catecholamine levels, presumably due to either dysfunctional calcium handling within 
the cardiomyocytes or catecholamine-induced βAR down-regulation(11-14).  The lack of CAD and 
hypertension in DCM, even in the presence of elevated catecholamines, suggests that 
hyperinsulinemia elicits direct cardiomyocyte insult, possibly by modulating adrenergic function.  
Together, these data illustrate the potential importance of βAR/insulin receptor (IR) interactions 
in the hearts of diabetic patients.  The mechanism and consequence of these interactions remains 
to be elucidated. 
 
Adrenergic receptor structure and expression 
The adrenergic receptors make up a class of heterotrimeric guanine nucleotide–binding 
protein (G protein)–coupled receptors (GPCRs) that play a central role in mediating the effects of 
catecholamine hormones.  GPCRs, the most ubiquitous receptors in the body, link ligand binding 
to G protein activation and signal transduction (Fig 1.2).  The adrenergic receptors are 
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prototypical G protein-coupled receptors comprised of seven hydrophobic transmembrane helical 
domains with an extracellular amino terminus and an intracellular carboxyl terminus(15-18) (Fig 
1.3).  While the third, fifth and sixth transmembrane domains are essential for agonist binding, 
the third intracellular loop and C-terminus are important in G protein coupling(19-21).  Further, 
receptor desensitization and internalization is mediated by the intracellular carboxyl terminus(22, 
23).   
Nine subtypes of adrenergic receptors exist (β1, β2, β3, α1A, α1B, α1D, α2A, α2B, α2C).  
These subtypes are widely expressed throughout the body.  In humans the β1AR is predominately 
expressed in cardiac tissues with minor expression in the kidney and gastrointestinal system(24).  
Conversely, the β2AR is predominantely expressed in the heart, lungs, skeletal muscle, liver and 
the uterus(24).  The β3AR is predominately expressed in both brown- and white adipose tissue, the 
gastrointestinal tract and the prostate with minor expression in the heart(24).  The α1ARs are 
expressed in the heart, liver, lung, prostate, spleen, kidney, brain and the aorta(25, 26).  Conversely, 
the α2ARs have been detected in the brain, spleen, kidney, lung, prostate and heart(27).  The 
ubiquitous expression of the adrenergic receptors throughout the body clearly underscores the 
essential roles of these receptors in many diverse physiological processes.   
 
Classical and non-traditional adrenergic signaling within the heart 
Classical adrenergic signaling. Although nine subtypes of adrenergic receptors exist 
(β1, β2, β3, α1A, α1B, α1D, α2A, α2B, α2C), human and murine hearts predominately express the 
β1, β2- and α1 subtypes(28).  Adrenergic receptor subtypes modulate unique responses to 
catecholamine stimulation by activating different signaling pathways.  Upon stimulation, the 
β1AR couples to the Gs-protein which, in turn, activates a signaling cascade leading to cAMP 
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accumulation and protein kinase A (PKA) activation(28, 29).  In addition to Gs, β2ARs are also 
known to uniquely couple to inhibitory Gi proteins, which inhibit adenylyl cyclase activation, 
thus reducing PKA activation(29-31).  Alternatively, stimulation of the α1AR leads to both Gq and 
Gi coupling and subsequent phospholipase C (PLC) activation causing an increase in Ca2+ levels 
and protein kinase C (PKC) activation(28, 29, 32).  
The adrenergic receptors modulate many physiological processes within the heart 
including chronotropy and inotropy as well as cardiomyocyte growth and survival (Fig 1.3).  
Acute activation of βARs represents the primary mechanism to increase cardiac performance 
under stress.  Conversely, α1 adrenergic activation is essential in cardiac myocyte survival and 
growth as well as cardiac fibroblast proliferation and fibrosis.  Chronic stimulation of the ARs, 
however, has been implicated in numerous stages of cardiac remodeling including 
cardiomyocyte hypertrophy(33, 34) and apoptosis(30, 35, 36).   
Both β1 and β2ARs are prototypical GPCRs expressed in animal hearts.  βARs mediate 
increases in cardiac contraction upon agonist stimulation through the Gs-adenylyl cyclase-cAMP 
dependent protein kinase A (PKA) pathway(28, 29) (Fig 1.4).  Conversely, β2ARs are also known 
to uniquely couple to inhibitory Gi proteins leading to inhibition of adenylyl cyclases to reduce 
cardiac contraction, and initiation of anti-apoptotic and cell growth signaling(29, 37, 38) (Fig 1.4).   
In addition to their roles in contractility, studies have implicated cardiac adrenergic 
receptors in the pathological remodeling leading to heart failure under chronic stimulation by 
elevated circulating plasma catecholamines and increased sympathetic tone.  Evidence suggests 
distinct roles of the individual cardiac βAR and α1AR subtypes in pathological hypertrophic 
remodeling.  Chronic stimulation of the β1AR is cytotoxic in vitro, leading to myocyte death and 
eccentric remodeling in vivo(28, 29, 35).  In heart failure, β1AR expression is down regulated 
6 
 
although the mechanism, consequence and time point when this occurs are unknown(5).  
Conversely, β2AR signaling is cardioprotective and opposes β1AR-induced cytotoxicity(28, 29, 35).  
Alternatively, stimulation of the α1AR signaling pathway induces hypertrophic signaling in 
vitro(30, 39) leading to concentric remodeling observed in compensatory hypertrophy in vivo.  In 
particular, gene deficiency studies reveal α1ARs as the major AR subtypes responsible for 
cardiac hypertrophy in animals(34, 40, 41).  Further, chronic stimulation of both the α1AR(40, 41)  and 
the β1AR(42-46) are linked to catecholamine-induced cardiac remodeling in vivo.  The α1AR and 
βARs modulate hypertrophic signaling upon catecholamine stimulation by activating different 
signaling pathways.  These pathways transduce their hypertrophic signal by activating members 
of the MAP kinase family, including the ERK1/2 (P44/P42) MAPK which translocate to the 
nucleus to activate transcription factors important in cellular differentiation, proliferation, and 
growth(47). 
 Non-traditional adrenergic signaling. Traditionally, the adrenergic receptors undergo 
conformational changes upon agonist stimulation that expose intracellular binding sites for the 
heterotrimeric G proteins within the third intracellular loop(19-21).  The recruited G proteins 
exchange GTP for GDP, leading to the dissociation of G proteins into activated α subunit and βγ 
dimers. The dissociated G proteins then trigger the activation of specific effector proteins (e.g. 
adenylate cyclase, phospholipase C).  Second messengers, including cAMP, inositol 
trisphosphate and Ca2+, are subsequently generated and induce a range of biological outcomes.  
Under the continued presence of agonist, the agonist-occupied receptor is phosphorylated on the 
cytoplasmic carboxyl terminus by G-protein receptor kinases (GRKs)(22, 23, 48, 49).  Once 
phosphorylated by GRKs, arrestin proteins are recruited to the receptor leading to receptor 
internalization via clathrin-coated pits(50).  This leads to receptor desensitization, a state in which 
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receptor no can no longer respond to further agonist stimulation (Fig 1.5).  In addition to their 
roles in receptor desensitization and internalization, arrestin proteins have recently been shown 
to serve as adaptor proteins that facilitate the activation and subcellular localization of signaling 
cascades, including MAPK cascades(50-54)  (Fig 1.6).  Specifically, β arrestin 1 (also known as 
arrestin 2) and β arrestin 2 (also known as arrestin 3) facilitate ERK MAPK activation from both 
the β1AR(55) and the β2AR(51, 56).  This G protein-independent mechanism leads to cytoplasmic 
ERK retention and presumably phosphorylation of cytoplasmic targets, which modulate cellular 
function.    
 
Adrenergic interactions in cardiac remodeling 
βAR/α1AR interactions.  Despite extensive studies investigating the regulation of 
individual GPCR signaling cascades, the effect of concomitant GPCR activation by endogenous 
stimuli on downstream signaling remains poorly understood.  There is a great deal of evidence 
supporting functional cross-talk between different GPCRs, such as between the β1AR and the 
angiotensin 1 receptor(57), the α2AR and  the opioid receptors(58), as well as the c5a receptor and 
the UDP receptor(59) both in vitro and in vivo(57, 58, 60, 61).  The majority of these studies focus on 
short-term stress responses involved in modulation of common effectors such as G proteins, 
phospholipases, and adenylyl cyclases(61, 62).  Endogenous catecholamine stimulation activates 
both βAR and α1AR signaling cascades, however, the concomitant activation of adrenergic 
signaling in the heart under chronic disease conditions is not known.  Increasing evidence has 
implicated the importance of α1AR and βAR interactions in the modulation of signaling 
pathways in the heart(29, 63-65).  These interactions occur either at the receptor level via physical 
interactions between the receptors, or downstream of the ARs via signaling pathway cross-talk.  
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It has been shown that α1ARs and βARs form heterodimers(66, 67) and this interaction regulates 
receptor ontogeny, pharmacological diversity, signaling and regulation(68).  Alternatively, Gs 
stimulation inhibits Gq signaling via elevated regulator of G-protein signaling 2 (RGS2 levels(69).  
Furthermore, Gq-induced PLC-β1 activity is inhibited by Gs-induced PKA(70).  Together, these 
results suggest that βAR signaling may negatively regulate α1AR signaling at the receptor level 
or down-stream.   
 βAR/IR interactions.  In addition to adrenergic cross-talk, βARs have been shown to 
interact with receptor tyrosine kinases (RTKs) including the epidermal growth factor receptor(55, 
71, 72), platelet-derived growth factor receptor(73, 74) and insulin-like growth factor receptor(75, 76).  
Although the link between diabetes and heart failure has been established, the cellular 
mechanism remains unknown.  Due to the high metabolic demand of cardiac cells during 
adrenergic stimulation, the interaction between βARs and the IR, within the heart represents a 
potentially essential mechanism leading to cardiac remodeling observed in diabetic patients.  IRs 
and βARs induce heterologous signal transduction pathways leading to opposing cellular 
processes.  IR, a member of the large RTK family, phosphorylates Insulin receptor substrate 
(IRS-1) leading to GLUT4 expression in effector cells. Increased GLUT4 expression on the 
cellular membrane induces glucose transport into the cell leading to anabolic processes.  In 
addition, IRS-1 phosphorylation induces PI3K-mediated AKT activity leading to cardiac 
hypertrophy(77-79).  Conversely, ligand binding to the βARs, prototypical members of the G 
protein-coupled receptor superfamily, induces cAMP-dependent protein kinase A (PKA) 
activation and phosphorylation of Phospholamban (PLN) leading to increased 
Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) channel activity(28, 29, 80).  Elevated 
SERCA activity increases myocyte contractility, stroke volume and cardiac output(81).   
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 Despite the different signaling mechanisms, insulin and adrenergic signaling is shown to 
interact to influence each other’s signaling in adipocytes and liver cells.  Two possible locations 
exist for IR/βAR cross-talk: the receptor level and down-stream signaling components.  In 
adipocytes, IR activation leads to increased βAR down-regulation via phosphorylation of the 
β2AR(76, 82-86).  This phosphorylation of the β2AR by insulin-induced signaling pathways 
promotes insulin-induced β2AR internalization in 3T3-L1 adipocytes and human epidermoid 
carcinoma A431 cells.  Conversely, IGF-1 induces PI3K/Akt-dependent phosphorylation of 
β1AR in CHO cells(87). 
 Meanwhile, other signaling proteins in GPCR signaling pathways also participate in RTK 
signaling cascades.   In particular, the Gi protein is shown to be essential in glucose transport and 
insulin resistance in adipocytes and hepatocytes(88).  IRs have also been shown to recruit 
GRKs(91, 92) and the scaffold/adaptor protein β-arrestin(93-95).  Conversely, IGF-1-mediated MAP 
kinase (MAPK) phosphorylation is dependent on Gαi/βγ signaling(89, 90), or β arrestin 1 (96-98). 
Further, down-regulation of β arrestin 1 by insulin treatment can impair MAP kinase signaling 
by both GPCRs and RTKs(99). 
 However, few studies have implied functional interactions between IRs and βARs in 
cardiac tissues.  Insulin inhibits β-adrenergic action in the ischemic/reperfused heart to protect 
cardiac myocytes(100), and PI3K offsets cAMP-mediated positive inotropic effect via inhibiting 
calcium influx in cardiac myocytes(101).  In contrast, Akt activated by βAR/PKA signaling is 
involved in phosphorylation of the IR for insulin resistance in cardiac myocytes(102). The 
mechanism and effects of decreased insulin signaling in response to βAR stimulation on cardiac 
remodeling remain largely unknown.  Due to the high correlation between diabetes and cardiac 
remodeling as well as the intimate interactions between the βARs and IRs within the body, the 
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interactions between the βARs and the IRs within the heart represent a potentially essential 
mechanism to explain the link between diabetes and heart failure.  
 
Clinical significance 
 Nearly sixty years after the discovery of the ARs, the 1960s witnessed not only the 
merger of biochemistry with pharmacology in the adrenergic receptor field, but also the 
utilization of βAR antagonists in clinical medicine(103).  Fifty years later, the cellular mechanisms 
of βAR blockade remain unknown.  Clinically, βAR antagonists, including carvedilol, are 
effective long-term therapies for hypertension, cardiomyopathy and heart failure(104-110).  
Although carvedilol has been used as an effective long-term therapy for heart failure, other drugs 
in the same class have been less successful or have failed in clinical trials(111).  In particular, the 
COMET trial showed that combined α1AR and β1AR antagonism via carvedilol treatment led to 
decreased mortality over metoprolol treatment, which blocks β1AR alone(110).  In addition, 
insulin treatment increases the risk of mortality in HF patients(112).  Conversely, β blockade with 
either metoprolol(113) or carvedilol(114) results in significant mortality reduction compared to 
placebo in diabetic patients.  These observations strongly suggest that a more defined 
understanding of the interactions between adrenergic receptors and other cardiac-relevant 
receptors is needed to improve the clinical utility of βAR antagonists in cardiovascular diseases, 
particularly heart failure.  It is critical to understand the consequences of either activation or 
inhibition of adrenergic receptors in the hypertrophic growth of the heart.  With this 
understanding, more efficient pharmacologic agents may be developed to prevent the progression 
of this major health problem. 
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Aims 
 Understanding how cells integrate information from a variety of chemically diverse 
signals into complex, orchestrated responses such as cell proliferation, differentiation and 
apoptosis is an overarching goal of cell biology.  Adrenergic signaling within the heart represents 
essential signaling cascades regulating both cardiac performance as well as pathophysiological 
remodeling.  Due to the complexities of hormonal signaling in vivo, it is essential to understand 
how concomitant activation of one signaling pathway can alter the physiologic outcome of 
another receptor’s signaling.  These studies not only underscore the critical role of signaling 
cross-talk in the complex regulation of receptor signaling via sub cellular localization of 
signaling components, but also provide novel mechanisms into the regulation of mitogenic 
signaling elicited by different receptors.   
 Broadly, with these following studies we hope to elucidate novel and physiologically 
relevant signaling cross-talk mechanisms and define their role in pathophysiological cardiac 
remodeling.  An understanding of the mechanisms and physiologic consequences of adrenergic 
receptor cross-talk within the heart is essential to develop novel treatments designed to prevent 
cardiac remodeling and heart failure.  The aims outlined below, which utilize a spectrum of 
physiological and cell biology techniques, will answer these basic questions and set a foundation 
for future areas of investigation. 
  Aim 1: To characterize the cellular mechanism by which GPCR cross-talk regulates 
mitogen-activated protein kinase (MAPK) activation and define how this regulation affects 
cellular proliferation. 
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 Aim 2: To determine the mechanism by which type II RTK activation at high 
concentrations of mitogen recruits non-traditional GPCR signaling components to fine-tune 
activation of MAPK signaling and define how this regulation affects cellular proliferation.   
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Figures & Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Stereotypical progression of cardiac remodeling leading to heart failure. Chronic hypertension 
(hemodynamic stress) elevates circulating blood catecholamines, leading to an initial compensatory cardiac 
hypertrophy (hypertrophic cardiomyopathy or concentric hypertrophy).   Prolonged exposure to catecholamines 
induces myocyte apoptosis and fibroblast proliferation (dilated cardiomyopathy or eccentric hypertrophy).  This 
weakens the left ventricular wall leading to eventual heart failure.  Figure modified from www.ipmc.cnrs.fr and 
http://www.daviddarling.info/encyclopedia/C/cardiomyopathy.html 
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 Figure 1.2. GPCR signaling pathways. GPCRs, including the adrenergic receptors, respond to a diverse variety of 
agonists, including both chemical and physical.  Upon activation, conformational changes in the GPCR induce 
coupling to specific G proteins.  This G protein coupling determines the consequence of GPCR activation by 
inducing distinct second messenger signaling pathways.  Figure modified from 
http://isoft.postech.ac.kr/Research/POSBIOTM/content/intro.html 
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Figure 1.3. Crystal structure of the β2 adrenergic receptor. The adrenergic receptors, prototypical G-protein 
coupled receptors, are comprised of seven transmembrane hydrophobic domains with an extracellular N terminus 
and a cytoplasmic C terminus.  Here, the β2AR is shown binding its inverse agonist carazolol. Figure obtained from 
Cherezov et. al. 2007 and Rosenbaum et. al. 2007(17, 18). 
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Figure 1.4. Adrenergic signaling in the heart. Within the heart, the β1AR, β2AR and α1AR induce unique, but 
overlapping signaling pathways to modulate cardiac contraction, survival and growth.  Figure obtained from Xiao et. 
al. 2006(29). 
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Figure 1.5. β2AR desensitization upon agonist stimulation. Upon agonist binding, the β2AR is phosphorylated on 
the cytoplasmic C-terminus by GPCR kinases (GRKs).  This phosphorylation event recruits arrestin proteins to the 
receptor leading to receptor desensitization and internalization via clathrin-coated pits. Figure obtained from Pierce 
and Lefkowitz 2007(50). 
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Figure 1.6. Arrestin-mediated scaffolding of MAPK signaling components.  In addition to receptor 
internalization, arrestin proteins function as adaptor proteins to scaffold components of MAPK (ERK and JNK) 
signaling pathways.  This offers a unique mechanism by which arrestin proteins can dictate the spatiotemporal 
activation of mitogenic signaling pathways.  Figure obtained from Pierce and Lefkowitz 2007(50). 
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Chapter 2: 
 Arrestin orchestrates cross-talk between GPCRs to modulate the 
spatiotemporal activation of ERK MAPK  
Abstract 
G protein-coupled receptors (GPCRs) respond to diversified extracellular stimuli to modulate 
cellular function. Despite extensive studies investigating the regulation of single GPCR signaling 
cascades, the effects of concomitant GPCR activation on downstream signaling and cellular 
function remain unclear.  We aimed to characterize the cellular mechanism by which GPCR 
cross-talk regulates mitogen-activated protein kinase (MAPK) activation.  Adrenergic receptors 
on cardiac fibroblasts were manipulated to examine the role of arrestin in the spatiotemporal 
regulation of extracellular signal-regulated kinase (ERK)1/2 MAPK signaling. We show a 
general mechanism in which arrestin activation by one GPCR is capable of regulating signaling 
originating from another GPCR. Activation of Gq coupled-receptor signaling leads to prolonged 
ERK1/2 MAPK phosphorylation, nuclear accumulation, and cellular proliferation. Interestingly, 
coactivation of these receptors with the β-adrenergic receptors induced transient ERK signaling 
localized within the cytoplasm, which attenuated cell proliferation. Further studies revealed that 
recruitment of arrestin 3 to the β2-adrenergic receptor orchestrates the sequestration of Gq-
coupled receptor-induced ERK to the cytoplasm through direct binding of ERK to arrestin.  This 
is the first evidence showing that arrestin 3 acts as a coordinator to integrate signals from 
multiple GPCRs. Our studies not only provide a novel mechanism explaining the integration of 
mitogenic signaling elicited by different GPCRs, but also underscore the critical role of signaling 
cross-talk among GPCRs in vivo.  
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Introduction 
 G protein-coupled receptors (GPCRs) respond to the most diversified extracellular 
stimuli to modulate cellular function.  Activated receptors catalyze GDP/GTP exchange on 
cognate G proteins, which transduce downstream signals via second messengers and membrane 
channels 1.  Active GPCRs are phosphorylated by specific G-protein-coupled receptor kinases 
(GRKs) leading to receptor desensitization.  Arrestin proteins, including arrestin 2 (also known 
as β arrestin 1) and arrestin 3 (also known as β arrestin 2) then bind to the phosphorylated 
receptor inducing clathrin-mediated internalization 2.  Despite extensive studies investigating the 
regulation of single GPCR signaling cascades, the effect of concomitant GPCR activation by 
endogenous stimuli on downstream signaling remains poorly understood.  There is a great deal 
of evidence supporting functional cross-talk between different GPCRs both in vitro and in vivo 3-
6.  The majority of these studies focus on short-term stress responses involved in modulation of 
common effectors such as G proteins, phospholipases, and adenylyl cyclases 5, 7.  However, 
chronic activation of multiple GPCR signaling pathways during adaptive tissue and organ 
remodeling suggests the potential of downstream cross-talk away from the plasma membrane. 
 One potential nexus for GPCR signaling cross-talk are the multi-functional scaffold 
proteins known as arrestins.  Arrestins not only scaffold proteins necessary for the activation of 
different MAPK kinase families under single receptor activation, but also mediate transactivation 
of epidermal growth factor receptor signaling pathways 2, 8 and activation of many other non-
GPCR signaling cascades 9.  In the case of GPCR-induced MAPK ERK activation, both G 
proteins and arrestins are capable of mediating ERK activation via independent mechanisms, 
with each pathway leading to unique spatiotemporal consequences 10.  While G-protein-activated 
ERK translocates to the nucleus for gene transcription, arrestins activate the ERK within the 
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cytoplasm.  Since arrestins preferentially bind to some, but not all, GPCRs in a ligand-dependent 
manner, we envision that arrestins may play a role in GPCR cross-talk to coordinate MAPK 
activation in distinct subcellular compartments.  Such a regulatory mechanism is essential for 
modulating MAPK signaling in divergent cellular functions such as cell proliferation and growth 
11, 12, stress responses such as promoting cell mobility 13, and inhibiting cell apoptosis 14. 
 We choose cardiac fibroblasts as a model to study GPCR signaling cross-talk.  Both 
α1ARs and βARs are expressed in cardiac tissue and are activated by catecholamines to modulate 
cardiac remodeling including cardiac fibroblast proliferation by activation of distinct pathways.  
These pathways transduce signal by members of the MAP kinase family, including ERK1/2.  
Stimulation of the α1AR leads to Gq coupling and subsequent phospholipase C (PLC) and 
protein kinase C (PKC) activation 15.  PKC has been shown to directly activate the Raf-MEK1-
ERK axis.  The activated ERK is translocated to the nucleus for gene transcription important in 
cellular differentiation, proliferation, and growth 16.  Meanwhile, stimulation of βAR signaling 
leads to ERK activation in a Gi-dependent manner via Gβγ subunits 17.  Alternatively, activated 
βARs associate with arrestins leading to receptor internalization and arrestin-mediated ERK 
activation from both the β1AR 18, and the β2AR 10.  The later G protein-independent mechanism 
leads to cytoplasmic ERK retention and presumably phosphorylation of cytoplasmic targets.  
 Here we have identified a novel mechanism regulating Gq-coupled receptor-induced 
MAPK signaling via cross-talk with βAR-recruited arrestin in mouse cardiac fibroblasts and 
embryonic fibroblasts (MEFs).  This is the first evidence suggesting that arrestin activation by 
one GPCR is capable of regulating a signaling pathway originating from another GPCR.  These 
studies not only underscore the critical role of signaling cross-talk in the complex regulation of 
receptor signaling via subcellular distribution, but also provide a novel mechanism explaining 
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the coordination of subcellular mitogenic signaling elicited from different GPCR stimuli.  
Understanding regulatory cross-talk among GPCR signals will be critical for new 
pharmacological strategies aimed at preventing and treating the progression of a variety of 
diseases. 
 
Materials & Methods 
Cell culture, transfection, and adenoviral infections  
 Animal protocols are approved by the IACUC of the University of Illinois according to 
NIH regulation. Cardiac fibroblasts were isolated from the hearts of either wild-type, β1KO or 
β2KO neonatal FVB mice by a collagenase dispersion procedure utilizing a preplating step to 
remove cardiac myocytes as detailed in previous publications 1, 2. Cells were cultured on 10 cm 
tissue culture treated dishes until 90% confluent. Cells were then plated on 35 mm tissue culture 
treated dishes at a confluency of 60-70%. Primary cardiac fibroblasts were maintained for 24 h in 
DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and experiments 
were performed, unless otherwise noted, on cells serum-deprived for 24 h. Wild type, as well as 
arrestin 2 (also known as β arrestin 1) knock out (KO) , arrestin 3 (also known as β arrestin 2) 
KO and arrestin 2/3 double knock out (DKO) Mouse Embryonic Fibroblasts (MEFs) were 
maintained 24 h in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum. FLAG-tagged mouse arrestin 3 constructs were transfected into primary neonatal cardiac 
fibroblasts utilizing Lipofectamine2000 (Invitrogen, Carlsbad, CA). Alternatively, neonatal 
cardiac fibroblasts were infected with recombinant adenoviruses as indicated after being cultured 
for 24 h. Recombinant plasmids expressing βARKct, GFP- arrestin 3, and GFP- arrestin 3 V54D 
have been generated as previously described 2, 4. GFP- arrestin 3 and GFP- arrestin 3 V54D 
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plasmids were gifts from Dr. Gang Pei (Chinese Academy of Sciences, Shanghai). Dominant 
negative Src plasmids were gifts from Dr. Qin Wang (University of Alabama at Birmingham). 
Mouse embryonic fibroblasts (MEF) cell lines were from Dr. Robert Lefkowitz (Duke 
University). GRK3ct is a gift from Dr. Blaxall Burns (University of Rochester). Co-
immunoprecipitation experiments were conducted after 48 h expression. 
Drug Treatment  
 Fibroblasts were treated with the following agonists or antagonists for the indicated 
times: epinephrine (Epi, 10 μM; Sigma, St. Louis, MO) or norepinephrine (NE, 10 μM; Sigma, 
St. Louis, MO) as general AR agonists, phenylephrine (Phe, 10 μM; Sigma, St. Louis, MO) as an 
α1AR agonist, isoproterenol (Iso, 10 μM; Sigma, St. Louis, MO) as a βAR agonist, clonidine 
(Clo, 10 μM; Sigma, St. Louis, MO) as an α2AR agonist, timolol (Tim, 10 μM; Sigma, St. Louis, 
MO) as a βAR antagonist, prazosin (Prz, 10 μM; Sigma, St. Louis, MO) as an α1AR antagonist, 
yohimbine (Yoh, 10 μM; Sigma, St. Louis, MO) as a α2AR antagonist, (Val5)angiotensin II 
(1μM; Sigma, St. Louis, MO) as an angiotensin agonist, thrombin (1nM; Sigma, St. Louis, MO) 
as a thrombin receptor agonist, phorbol 12-myristate 13-acetate (PMA, 10uM; Sigma, St. Louis, 
MO) as a PKC agonist. Fibroblasts were treated with the following inhibitors for the indicated 
times: persussis toxin (PTX, 500 ng/mL; Sigma, St. Louis, MO) as a Gi specific inhibitor, 
U73122 (1 μM; Calbiochem, San Diego, CA) as a non-specific phospholipase C (PLC) inhibitor, 
N-[2-(p-Bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide dihydrochloride; (H89, 10 
μM; Sigma, St. Louis, MO) as a protein kinase A (PKA) inhibitor, or the membrane-permeable 
myristoylated PKC inhibitor fragment 19-27 (PKCi, 100 μM; MP Biomedicals, Irvine, CA). 
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Immunoblotting  
 Antibodies specific to both phosphorylated and total ERK1/2 were purchased from Cell 
Signaling (Danvers, MA). Fibroblasts were starved for 24 h prior to the addition of 10 μM of the 
indicated agonist or antagonist for the indicated times. Alternatively, fibroblasts were pretreated 
with inhibitors as indicated in the figure legends. After stimulation, fibroblasts were chilled, 
washed, and harvested in lysis buffer (5 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% NP-40, 2.5 mM 
Na4P2O7, 2.5 mM NaF, 0.5 mM PMSF, 40 μg ml-1 leupeptin and aprotinin). Lysates were 
clarified and resolved on 10% SDS-PAGE gels for western blot. In order to obtain nuclear 
extracts, stimulations were stopped on ice with PBS containing Ca2+ and Mg2+. Cells were 
scraped in hypotonic buffer (5mM NaCl, 20mM HEPES, 2.5mM PMSF, 2mM EDTA, 40μg/ml 
leupeptin and aprotinin, 10mM NaF, 1mM NaVO4, 0.4% NP-40) and disrupted by mechanical 
lysis. Nuclear extracts were pelleted by centrifugation at 12,000g for 1 min and resuspended in 
hypotonic buffer. Nuclear and cytoplasmic extracts were resolved via SDS PAGE. Signal 
intensity was quantitated by densitometry of Western blots. Phosphorylated and total ERK were 
detected via incubation with the corresponding antibodies (1:1000, Cell Signaling, MA) at 
1:1000 for 2hr RT. Primary antibodies were visualized with IRDye 680CW goat-anti mouse or 
with IRDye 800CW goat-anti rabbit secondary antibodies using an Odyssey scanner (1:10,000; 
LI-COR Biosciences, Lincoln, NE). Phospho-ERK signals were corrected for total ERK levels 
and plotted as increase over basal levels. 
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Immunofluorescence microscopy  
 Fluorescent images were taken with a Zeiss Axioplan 2 microscope (Carl Zeiss Inc., 
Thornwood, NY) with an attached CCD camera and Metamorph software (Molecular Devices, 
Sunnyvale, CA). Cells were plated on laminin coated coverslips and then serum starved for 24 h. 
Fibroblasts were then stimulated with 10 μM of the indicated agonists or antagonists for the 
indicated times. Cells were then fixed with 4% paraformaldehyde for 1 hr at 4oC and then 
permeabilized with PBST (0.1% Triton X-100 in PBS) for 15 min at RT, rinsed and blocked, and 
then incubated with 1:400 HA antibody or 1:400 ERKp antibody diluted in PBST 2 hr at RT. 
AlexaFluor-594-conjugated goat anti-mouse IgG1 antibody or AlexaFluor- 488-conjugated goat 
anti-rabbit IgG1 were utilized as the secondary antibody at 1:1000 diluted in PBST with 10% 
FBS for 1 hr at RT. 
Co-immunoprecipitation  
 Wild-type MEFs were transfected with FLAG-tagged mouse βAR together with either 
GFP-arrestin 3 or together with FLAG-tagged α1A-AR, α1B-AR, α1D-AR, or β2AR constructs as 
described above. MEFs were stimulated with 10 μM of the indicated agonist or antagonist for 10 
min before being lysed with lysis buffer. Lysates were cleared by centrifugation and subjected to 
immunoprecipitation with M2 anti-FLAG affinity resin (25 μL, Sigma, St. Louis, MO). The 
immunoprecipitates were resolved via SDS-PAGE and blotted with antibodies against ERK 
(1:500, Cell Signaling, MA), FLAG (1:1,000; Sigma, St. Louis, MO), HA (1:1000, Covance, 
CA), GFP (1:1000, Rockland Immunochemicals, PA), or γ tubulin (1:5,000; Sigma, St. Louis, 
MO). Primary antibodies were visualized with IRDye 680CW goat anti mouse or with IRDye 
800CW goat-anti rabbit secondary antibodies using an Odyssey scanner (LI-COR Biosciences, 
Lincoln, NE). 
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Reverse Transcriptase PCR  
 RNA was extracted from neonatal cardiac fibroblasts according to protocol supplied with 
the Aurum total RNA minikit (Biorad, Hercules, CA). cDNA was created and amplified via PCR 
in a one step method using the protocol supplied with the Access RT-PCR system (Promega, 
Madison, WI). Briefly, 100ng RNA was amplified using 2mM MgSO4 utilizing the following 
thermocycler profile: reverse transcription at 45oC for 45 min, deactivation of reverse 
transcriptase at 94oC for 2 min, 45 cycles of denaturation at 94oC for 1 min, annealing at 57oC 
for 1 min and extension at 68oC for 1 min. Primers against α1A-AR (forward: 5'-
GTAGCCAAGAGAGAAAGCCG-3; reverse: 5’-CATCCCACCACAATGCCCAG-3') α1B-AR 
(forward: 5’-GCTCCTTCTACATCCCACTGG- 3’; reverse: 5’-
AGGGGAGCCAACATAAGATGA-3’) and α1D-AR (forward: 5’- 
CGTATGCTCCTTCTACCTCCC-3’; reverse: 5’-GCACAGGACGAAGACACCCAC-3’) were 
designed based on previous publications 5, 6. PCR products were visualized on a 2% DNA gel. 
Cardiac Fibroblast Cell Proliferation ELISA  
 The cell proliferation ELISA was carried out utilizing BrdU Labeling and Detection Kit 
III (Roche) according to the manufacturer’s instructions. Briefly, cardiac fibroblasts were 
cultured in a 96-well plate as described above and left overnight to attach. 10 μM BrdU was 
added to cells prior to drug stimulation for 8 hours at 37oC. Cells were then fixed and nucleases 
were allowed to partially digest cellular DNA. Cells were then incubated with an anti-BrdU 
antibody (200mU/ml) for 30 min at 37oC. Colorimetric analysis was performed with a 
Spectramax M2 fluorometer reader. The data were normalized against the control. 
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GRK Knockdown  
 GRK2, GRK3 and GRK5 shRNA plasmids were obtained from Sigma. WT MEF cells 
were co-transfected with a GRK shRNA plasmid and a YFP plasmid for visualization.  After 
overnight transfection, 10 μg/ml of puroymcin was added to dishes to select for positive 
transfection. After 48 hr puromycin selection, cells were serum starved for another 24 h. Cells 
were then either processed for imaging or harvested as described above for Western blot. Cell 
lysates were resolved via SDS-PAGE and blotted with antibodies against GRK2, GRK3 or 
GRK5 (SCBT,CA). Primary antibodies were visualized with IRDye 680CW goat-anti mouse or 
with IRDye 800CW goat-anti rabbit secondary antibodies using an Odyssey scanner (LI-COR 
Biosciences, Lincoln, NE). 
Statistical analysis  
Data analysis was performed using GraphPad Prism version 4.0 (GraphPad Software, San Diego 
CA). 
 
Results 
Agonist-dependent spatiotemporal activation of ERK upon stimulation of adrenergic 
receptors in cardiac fibroblasts 
 Both α1ARs and βARs are implicated in promoting ERK activation upon stimulation with 
catecholamines 12.  Utilizing cardiac fibroblasts, we investigated the mechanism leading to the 
modulation of ERK signaling upon potential cross-talk between these GPCRs.  We examined 
agonist-dependent ERK phosphorylation induced by epinephrine (Epi).  Since α1ARs are the 
primary adrenergic receptors responsible for ERK activation in cardiac tissues, we used the 
α1AR-specific agonist phenylephrine (Phe).  Both Epi and Phe activated ERK by increasing the 
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phosphorylation of ERK (phospho-ERK). The maximal phospho-ERK levels peaked at 5 
minutes after stimulation, with the peak levels induced by Phe significantly lower than that by 
Epi.  Moreover, the Epi-induced phospho-ERK underwent a rapid decrease to baseline, whereas, 
the Phe-induced phospho-ERK signal was prolonged and returned to baseline levels slowly (Fig 
2.1A). 
 Previous studies have indicated that subcellular ERK distribution may shape the temporal 
profile of ERK activation 18.  We found that Epi-induced phospho-ERK accumulated in the 
cytoplasm and returned to baseline levels rapidly (Fig 2.1B).  Interestingly, Phe-induced 
phospho-ERK translocated to the nucleus and remained elevated throughout stimulation (Fig 
2.1B).  The subcellular distribution of phospho-ERK was confirmed in fractionation studies.  The 
Epi-induced phospho-ERK was enriched in the cytoplasmic fraction; however, the Phe-induced 
phospho-ERK was enhanced in both the cytosolic and nuclear fractions (Fig 2.1C).  Thus, 
concomitant activation of the β and α1ARs by Epi induces a distinct spatiotemporal ERK signal 
than that elicited by activation of the α1AR alone by Phe. 
ERK activation is induced by a classical α1AR/Gq pathway in cardiac fibroblasts 
 To investigate the mechanism underlying the modulation of ERK signaling upon 
adrenergic receptor cross-talk, we first examined which adrenergic receptor was responsible for 
ERK phosphorylation.  Stimulation with Epi and Phe induced potent ERK activation (Fig 2.2A). 
Stimulation with the βAR agonist isoproterenol (Iso) resulted in minimal ERK activation, 
whereas, stimulation of the α2ARs with clonidine (Clo) did not activate ERK (Fig 2.2A). In 
addition, pretreatment with the α1AR antagonist prazosin (Prz), but not the βAR antagonist 
timolol (Tim) or the α2AR antagonist yohimbine (Yoh), significantly blocked Epi-induced ERK 
activation (Fig 2.2B and data not shown).  As a control, Prz and Yoh, as well as a panel of β-
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blockers including Tim, propanolol, alprenolol, and cavedilol did not alter basal ERK levels 
(Supplementary Figure 2.I).  Previous studies show that activation of βARs can induce cell-
specific ERK activation 19.  Similar to neonatal cardiac fibroblasts, Iso induced minimal ERK 
phosphorylation in MEFs, and in both neonatal and adult cardiac myocytes.  In contrast, 
stimulation of βARs with Iso induced robust ERK phosphorylation in HEK293 cells 
(Supplementary Figure 2.II). Together, these results confirmed that ERK activation resulted 
primarily from α1AR stimulation in cardiac fibroblasts, which was supported by the expression 
of both α1AAR and α1BAR genes (Supplementary Figure 2.III).  Accordingly, stimulation of Gq 
with Pasteurella multocida toxin and stimulation of PKC with phorbol myristate acetate (PMA) 
was sufficient to induce potent ERK activation (Fig 2.2 and data not shown).  In contrast, direct 
inhibition of Gi with Pertussis toxin (PTX) had no effect on agonist-induced ERK activation 
(Supplementary Figure 2.IV).  Pretreatment with the PKA inhibitor H89, which blocks Gs 
signaling, also had no significant effect on agonist-induced ERK activation (Supplementary 
Figure 2.IV). Together, these data confirm that the α1ARs are the primary adrenergic subtypes 
responsible for ERK phosphorylation via Gq activation in cardiac fibroblasts. 
 Classic α1AR/Gq coupling activates phospholipase C to produce diacyl glycerol, leading 
to PKC activation.   Pretreatment with the PLC inhibitor U73122 significantly blocked both Epi- 
and Phe-induced ERK phosphorylation (Figs 2.2C and 2.2D).  Similarly, pretreatment with a 
myristolated PKC inhibitory peptide (PKCi) significantly prevented ERK activation upon either 
Epi or Phe stimulation (Figs 2.2C and 2.2D).  Moreover, inhibition of MEK with U1026 also 
prevented both Epi and Phe-induced ERK activation (Figs 2.2C and 2.2D).  These data confirm 
that α1AR-induced ERK signaling is dependent on activation of PLC and PKC leading to the 
Raf-MEK pathway 20. 
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βAR activation prevents nuclear translocation of α1AR-induced ERK activation and 
cardiac fibroblast proliferation 
 One possible explanation for the differences in the spatiotemporal ERK activation profile 
between Epi and Phe is that βAR activation by Epi may lead to cytoplasmic retention of α1AR-
induced phospho-ERK.  To test this hypothesis, we blocked the βARs with Tim before Epi 
stimulation.  Inhibition of the βARs with Tim redistributed the Epi-induced phospho-ERK to 
both the cytoplasm and the nucleus, resulting in a similar spatial profile to that induced by Phe 
(Figs 2.3A and 2.3B).  As a result, βAR blockade significantly prolonged the phospho-ERK 
signal (Fig 2.3C).  Moreover, simultaneous stimulation of βARs with Iso prevented nuclear 
translocation of Phe-induced phospho-ERK and promoted phospho-ERK signal attenuation 
(Supplemental Figure 2.V). Together, our data suggest that activation of βARs can prevent 
nuclear translocation of phospho-ERK induced by the α1AR/Gq signaling pathway. 
 To understand the physiologic consequence of cytoplasmic ERK sequestration upon 
α1AR and βAR cross-talk in cardiac fibroblasts, we examined cell proliferation utilizing BrdU 
incorporation upon different ligand stimulation. Activation of the α1ARs with Phe, but not the 
βARs with Iso, induced a significant increase in BrdU incorporation, which was blocked by the 
MEK inhibitor U1026.  Further, activation of both the α1AR and βARs with Epi did not 
significantly enhance BrdU incorporation. However, inhibition of βARs with Tim enabled Epi to 
stimulate BrdU incorporation (Fig 2.3D), presumably due to the redistribution of phospho-ERK 
to the nucleus for gene transcription (Fig 2.3A). This increase in BrdU incorporation was again 
blocked by U1026. 
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β2AR, but not β1AR, activation prevents nuclear translocation of α1AR-induced ERK 
activation  
 We then sought to identify the βAR subtype responsible for cytoplasmic sequestration of 
α1AR-induced ERK.  Cardiac fibroblasts lacking the β2AR, but not those lacking the β1AR, 
displayed nuclear phospho-ERK accumulation upon Epi stimulation (Figs 2.4A and 2.4B), which 
also prolonged the phospho-ERK signal (Fig 2.4C).  Stimulation of DKO cells, which lack both 
βAR subtypes, with Epi induced phospho-ERK in both the cytoplasm and nucleus (Figs 2.4D 
and 2.4E).  We then reintroduced either β1AR or β2AR into DKO cells with similar expression 
levels (data not shown). Expression of β2AR, but not β1AR, recovered the cytoplasmic retention 
of phospho-ERK induced by Epi (Figs 2.4D and 2.4E). Thus, the effect is β2AR-specific, and is 
not due to the higher endogenous expression levels of the β2AR than the β1AR in cardiac 
fibroblasts 21.  Together, these data suggest that activation of the β2AR modulates both the 
spatial and temporal profile of α1AR-induced ERK activation in cardiac fibroblasts. 
β2AR-dependent recruitment of arrestin is necessary to sequester α1AR-induced ERK 
signaling 
 We further examined the molecular mechanism explaining this signaling cross-talk. 
Previous studies reported that α1DARs form a heterodimer with β2ARs in HEK293 cells, thus 
altering α1D signaling 22, but this α1AR subtype is not expressed in cardiac fibroblasts 
(Supplementary Figure 2.III). Moreover, neither α1AAR nor α1BAR dimerized with β2AR 
(Supplementary Figure 2.VI). Alternatively, upon phosphorylation of the β2ARs via GRKs, 
arrestins are recruited leading to receptor internalization 23; and the internalized β2AR/arrestin 
complexes propagate numerous signaling pathways, including ERK pathways 24.  Due to their 
role in arrestin recruitment, we investigated the role of GRKs in Epi-induced ERK activation. 
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MEF cells were used for selective knockdown of individual GRKs. In wild-type MEF cells, Epi 
stimulated cytoplasmic phospho-ERK, similar to cardiac fibroblasts. Selective knockdown of 
GRK2, but not other GRKs, in MEF cells significantly promoted nuclear accumulation of 
phospho-ERK induced by Epi (Fig 2.5A and Supplementary Figure 2.VII). Expression of 
βARKct, a GRK2 inhibitor that prevents arrestin recruitment and thus βAR internalization 25, 
significantly promoted nuclear accumulation of phospho-ERK (Fig 2.5B) and prolonged ERK 
signaling (Fig 2.5C).  These data indicate that the GRK2-mediated phosphorylation of the β2AR 
modulates ERK activation, presumably through arrestin-mediated scaffolding of ERK.  
 In addition, Src is necessary for arrestin-dependent βAR internalization upon agonist 
binding 26.  Inhibition of Src with either over-expression of dominant negative Src (DN-Src) or 
treatment with Src inhibitor PP2 prolonged ERK activation induced by Epi, but had no effect on 
Phe-induced ERK (Supplementary Figure 2.VIII and data not shown).  Fractionation studies 
revealed that DN-Src expression enhanced nuclear phospho-ERK translocation upon Epi 
stimulation (Supplementary Figure 2.VIII).  These data suggest that Src-dependent and arrestin-
mediated β2AR internalization is necessary for cytoplasmic sequestration of the α1AR-induced 
ERK signal under Epi stimulation. 
 To identify the arrestin(s) responsible for this cross-talk, MEF cells lacking either arrestin 
2 (also known as β arrestin 1) or arrestin 3 (also known as β arrestin 2) were used.  In 
comparison to wild-type MEF cells, Epi promoted phospho-ERK translocation to the nucleus in 
arrestin 3 KO (arr3-KO), but not arrestin 2 (arr2-KO) MEF cells (Figs 2.6A and 2.6B). Thus, 
arrestin 3 is primarily responsible for the cross-talk between the β2 and α1ARs. We then 
examined the association between ERK and the β2AR/arrestin 3 complex upon agonist 
stimulation.  Epi induced a significant increase in the association between ERK and the 
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β2AR/arrestin 3 complex, which was attenuated by Tim (Fig 2.6C and Supplementary Figure 
2.IX).  In contrast, neither Phe nor Iso enhanced the association between ERK and the 
β2AR/arrestin 3 complex; but co-stimulation with Iso and Phe promoted formation of the 
complex (Fig 2.6C). Further, a dominant-negative arrestin 3 (GFP-V54Darr3 27) also formed a 
complex with the β2AR, but was not sufficient to promote the binding of ERK to the 
β2AR/arrestin 3 complex (Fig 2.6C).  We then used GFP-V54Darr3 to further perturb the cross-
talk between the β2 and α1ARs. Expression of GFP-V54Darr3, but not GFP-arr3, promoted 
nuclear translocation of the phospho-ERK induced by Epi, which did not colocalize with GFP-
V54Darr3 in the cytoplasm (Figs 2.6D and 2.6E).  In contrast, expression of neither GFP-arr3 
nor GFP-V54Darr3 affected the Phe-induced nuclear accumulation of phospho-ERK (Figs 2.6D 
and 2.6E). In cells expressing GFP-V54Darr3, the cytosolic and the nuclear accumulation of Epi-
induced phospho-ERK was further confirmed by fractionation studies (Fig 2.6F).  Not 
surprisingly, nuclear translocation also prolonged the Epi-induced phospho-ERK signal (Fig 
2.6G).  Together, these data show that internalization of the β2AR via arrestin 3 induces the 
cross-talk between the α1 and β2ARs, leading to ERK sequestration within the cytoplasm. 
Arrestin modulation of cellular ERK signaling via GPCR cross-talk is a general mechanism 
 To test whether this arrestin-mediated GPCR cross-talk is a general MAPK regulatory 
mechanism upon concomitant activation of multiple GPCRs, we used MEF cells lacking both 
arrestin 2 (also known as β arrestin 1) and arrestin 3 (also known as β arrestin 2) to investigate 
phospho-ERK distribution induced by different Gq-coupled receptors in the absence and 
presence of β2AR activation.  Stimulating both wild type MEFs and cardiac fibroblasts with 
either Phe or PMA induced nuclear accumulation of phospho-ERK.  Interestingly, stimulation of 
wild type MEF and cardiac fibroblast cells with two other Gq-coupled receptor agonists ((Val5) 
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angiotensin II or thrombin) also induced nuclear phospho-ERK accumulation (Figs 2.7A and 
2.7B), likely through Gq-dependent pathways 28.  However, upon Iso co-stimulation, Phe-, 
(Val5) angiotensin II-, thrombin-, as well as PMA-induced phospho-ERK was sequestered 
within the cytoplasm in both wild type MEF and cardiac fibroblast cells (Figs 2.7A and 2.7B).  
As expected, in MEF cells lacking arrrestins, or in cardiac fibroblasts expressing the GFP-
V54Darr3 mutant, ERK signaling induced by the different stimuli was able to translocate into the 
nucleus.  However, both arrestin deficiency and GFP-V54Darr3 expression blocked the effect of 
β2AR activation under Iso stimulation (Figs 2.7A and 2.7B).  Together, these data suggest that 
arrestin activation by the β2AR can sequester Gq-coupled receptor-induced phospho-ERK within 
the cytoplasm in both cardiac fibroblasts and MEF cells. 
 
Discussion 
 In this study, we have identified a novel mechanism regulating Gq-coupled receptor-
induced ERK MAPK signaling via cross-talk with β2AR-recruited arrestin 3 in cardiac 
fibroblasts and MEFs (Fig 2.8).  This is the first evidence suggesting that arrestin activation by 
one receptor is capable of regulating signaling originating from another GPCR.  G protein-
independent regulation of GPCR signaling via arrestins is an emerging mechanism explaining 
the regulation of a growing list of GPCR-mediated signaling including α2AR 18, angiotensin 
receptors 24, β1AR 17, β2AR 10, opioid receptors 29 and the vasopressin receptors 30, 31.  
Recruitment of arrestins to a phosphorylated GPCR regulates not only receptor internalization, 
but also intracellular signaling such as transactivation of receptor tyrosine kinases 2, 8.  Arrestin, 
in addition, scaffolds ERKs leading to activation, cytoplasmic retention 24, 32, and decreased 
transcription in the  nucleus 33.  In reconstituted systems this provides a linear mechanism, 
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however, this model fails to reflect the convoluted signaling networks in vivo.  Endogenous 
ligands, including neurotransmitters and hormonal peptides, bind to multiple receptors present in 
a cell, activating numerous signaling cascades.  Indeed, accumulative evidence supports signal 
cross-talk among GPCRs, such as between the β1AR and the angiotensin 1 receptor 6, the α2AR 
and  the opioid receptors 4, as well as the c5a receptor and the UDP receptor 34.  Here, our results 
suggest that arrestin functions as a master regulator, coordinating subcellular ERK activation 
under multiple extracellular stimuli to inhibit nuclear translocation and facilitate signal 
attenuation.  Considering the ability of arrestin to scaffold different cytoplasmic signaling 
components besides ERK, such as Src, JNK, and p38 28, and the ability of arrestin to selectively 
bind to some, but not all GPCRs in an agonist-dependent fashion 35, our data suggest a general 
mechanism of arrestin-mediated cross-talk among GPCRs with broad implications in 
physiological responses under neurohormonal regulation in vivo. 
 In cardiac fibroblasts and MEFs, our data indicate that the α1ARs make the primary 
contribution to ERK activation, supporting the dominant roles of these receptor subtypes in 
cardiac remodeling 36.  Consistent with previous studies 37, stimulation of the α1ARs with Phe 
induces the classic Gq-dependent activation of PLC and PKC, leading to ERK activation through 
Raf-MEK1 kinase cascade.  Under this signaling cascade, activated ERK translocates to the 
nucleus 37.  Interestingly, this scenario is completely reshaped when β2ARs are co-activated with 
the α1AR upon Epi stimulation.  Co-activation of the α1 and β2ARs leads to sequestration of 
phospho-ERK within the cytoplasm.  Under Epi stimulation, it was possible that two pools of 
ERK existed; a transient pool activated by the β2AR and a prolonged pool activated by the α1AR.  
The first pool becomes dominant simply because β2ARs are more prominent in cardiac tissues 
than α1ARs.  This explanation is unlikely for several reasons.  First, α1AR antagonist prazosin 
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blocked Epi-induced ERK phosphorylation.  Second, stimulation with isoproterenol (a βAR 
agonist) alone induces minimal ERK activation.  Third, blockade of the β2AR prolonged ERK 
activation and only slightly decreased maximal ERK levels (Fig 2.3C).  Taken together, these 
data support that ERK activation by Epi and Phe originates from α1AR activation.  However, 
under Epi stimulation, β2AR activation changes the spatiotemporal profile of ERK signaling by 
policing ERK to the β2AR/arrestin 3 complex.  Cytoplasmic retention may allow targeting to 
non-nuclear ERK substrates involved in different cellular stress processes 38 and receptor 
desensitization 39. This unique observation highlights the potential diversified physiological 
consequences under a given extracellular environment when multiple receptors are activated 
simultaneously. As expected, this arrestin 3-mediated cross-talk is dependent on the receptor 
phosphorylation by GRK. Inhibiting GRK2, but not other GRKs, is sufficient to prevent the 
β2AR-dependent modulation of α1AR-induced ERK signaling.  In addition to sequestering ERK 
within proximity of cytoplasmic ERK targets, our data indicate that interaction with arrestin 3 
may facilitate the attenuation of ERK signaling in the cytoplasm 40.  However, inhibition of 
phosphatase 2A or dual-specificity phosphatases (DUSPs) failed to prevent ERK 
dephosphorylation (data not shown), thus the phosphatases involved remain to be identified. 
 The distinct spatiotemporal profile of ERK activation induced by Gq-coupled receptors in 
the presence or absence of β2AR (and potentially other GPCRs) activation has broad implications 
in the maladaptative remodeling of different tissues in vivo.  Indeed, in cardiac myocytes, the 
β1AR, but not the β2AR appears to cross-talk with Gq-coupled receptors in modulating ERK 
activation (unpublished data).  Gq-coupled receptor signaling and ERK activation play essential 
roles in long-term pathophysiological cardiac remodeling 11, 36, 41.  Traditionally, activated ERK 
MAPK translocates to the nucleus to activate transcription factors including Elk-1 42 and GATA-
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4 43 leading to fibroblast proliferation and myocyte hypertrophy.  Here, this nuclear translocation 
of ERK is abrogated by arrestin binding to activated β2ARs in cardiac fibroblasts; interestingly it 
can be restored with the clinically-relevant β blocker timolol.  Our data thus provide insights into 
understanding the tissue remodeling observed in patients under chronic treatment with β-
blockers in various clinical and physiological conditions.   
  In summary, our findings provide the first evidence for the role of β2AR-recruited arrestin 
in regulating signaling from another GPCR.  These findings provide a novel mechanism to 
significantly advance our understanding of the growing profiles of GPCR regulatory pathways.  
These data further underscore the critical role of signaling cross-talk in the complex regulation of 
receptor signaling via subcellular localization of signaling components, which will have 
significant implications in numerous clinical and physiological conditions.   
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Figures & Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The temporal and spatial patterns of ERK activation are agonist-dependent.  A, Epi (10 µM) and 
Phe (10 µM) induced distinct temporal patterns of ERK phosphorylation in wild type (WT) cardiac fibroblasts.  B, 
Phosphorylated ERK was detected by immunofluorescence staining.  Epi (10 µM) induced transient cytoplasmic 
ERK phosphorylation whereas Phe (10 µM) induced prolonged nuclear ERK phosphorylation.  C, WT cardiac 
fibroblasts were treated with either Epi (10 µM) or Phe (10 µM) before being lysed and separated into nuclear and 
cytosolic fractions.  Epi induced transient cytoplasmic ERK phosphorylation whereas Phe induced prolonged 
cytoplasmic and nuclear ERK phosphorylation.  Phospho-ERK (ERKp) was normalized against total ERKT. N=4; *, 
p<0.05; **, p<0.01 by unpaired student t-test. 
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Figure 2.2.  ERK activation upon adrenergic stimulation occurs via α1AR signaling.  A, WT cardiac fibroblasts 
were stimulated with 10 µM of either Epinephrine (Epi), Isoproterenol (Iso), Phenylephrine (Phe), Clonidine (Clo) 
for 5 mins or PMA for 10 mins to obtain maximal stimulation.  B, WT fibroblasts were pretreated with 10 µM of 
either prazosin (Prz) or timolol (Tim) for 5 mins.  Cells were then stimulated with 10 µM of either Epi or Phe for 5 
mins or PMA for 10 mins. C and D, WT fibroblasts were pretreated for 30 mins with the PLC inhibitor U73122 (1 
μM), PKC inhibitor PKCi (20 μM), or a MEK inhibitor (1 μM), and then stimulated with either Epi or Phe for 5 
minutes. Phospho-ERK (ERKp) was normalized against total ERKT. N=3;  ***, p<0.001 by unpaired student t-test.         
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Figure 2.3. Inhibition of βAR activation permits nuclear localization of α1AR-induced ERK signal and 
stimulates cell proliferation.  A, WT cardiac fibroblasts were pretreated, if indicated, with the βAR antagonist Tim 
(10 µM) for 5 min and then stimulated with Epi (10 µM).  Cells were fixed for phospho-ERK (ERKp) staining. 
While Epi-induced ERKp signal was localized in the cytoplasm, Tim pretreatment relocated Epi-induced ERKp 
signal to the nucleus. B, WT fibroblasts were pretreated with Tim before Epi stimulation, the cells were then lysed 
and separated into nuclear and cytosolic fractions. C, WT fibroblasts were pretreated with or without Tim for 5 
minutes and then stimulated with Epi for the indicated times.  D. WT fibroblasts were pretreated with either Tim (10 
µM) or the MEK inhibitor (1 μM) for 30 minutes before stimulation with Iso (10 µM), Phe (10 µM), or Epi (10 µM) 
for 8 hours.  BrdU incorporation was measured, and the data were normalized against the control. Phospho-ERK 
(ERKp) was normalized against total ERKT. N=3; *, p<0.05; **, p<0.01; ***, p<0.001 by unpaired student t-test. 
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Figure 2.4. The β2AR, but not the β1AR,  prevents nuclear accumulation of ERK signal induced by α1ARs.  A, 
Fibroblasts were isolated from mice lacking either the β1AR (β1KO) or the β2AR (β2KO), cells were stimulated with 
Epi for 5 min and fixed for phospho-ERK (ERKp) staining.   B, β1KO or β2KO cardiac fibroblasts were stimulated 
with Epi for 5 min, the cells were then lysed and separated into nuclear and cytosolic fractions. C, β1KO or β2KO 
cardiac fibroblasts were stimulated with the indicated times.  D, Fibroblasts isolated from mice lacking both the 
β1AR and β2AR genes (DKO) were transfected with either HA- β1AR or HA- β2AR. Cells were stimulated with Epi 
for 5 min and fixed for phospho-ERK (ERKp) staining. E, DKO fibroblasts expressing either HA-β1AR or HA-
β2AR were stimulated with Epi for 5 min, the cells were then lysed and separated into nuclear and cytosolic 
fractions. Phospho-ERK (ERKp) was normalized against total ERKT.  N=3; *, p<0.05; **, p<0.01; ***, p<0.001 by 
unpaired student t-test. 
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Figure 2.5. GRK2, but not GRK3, mediates β2AR activation-dependent sequestration and attenuation of 
α1AR-induced ERK signal.  A, WT cardiac fibroblasts expressing GRK2, GRK3 or GRK5 shRNA were stimulated 
with Epi (10 µM) for 5 min and fixed for phospho-ERK (ERKp) staining. B, WT cardiac fibroblasts expressing HA-
tagged βARKct were stimulated with Epi (10 µM) for 5 min, the cells were either fixed for phospho-ERK (ERKp) 
staining or lysed and separated into nuclear and cytosolic fractions. C, WT cardiac fibroblasts expressing HA-tagged 
βARKct were stimulated with Epi (10 µM) the indicated times.  Phospho-ERK (ERKp) was normalized against total 
ERKT.  N=3. *, p<0.05; **, p<0.01; ***, p<0.001 by unpaired student t-test. 
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Figure 2.6. β2AR activation-dependent recruitment of arrestin 3 mediates sequestration and attenuation of 
α1AR-induced ERK signal.   A, WT, arr2 KO, and arr3 KO MEFs were stimulated with Epi (10 µM) for 5 min and 
fixed for phospho-ERK (ERKp) staining. B, Epi (10 µM, 5 min) stimulated cells were lysed and separated into 
nuclear and cytosolic fractions. C, WT fibroblasts expressing flag-β2AR together with either GFP-Arr3 or dominant 
negative GFP-V54DArr3 were stimulated with Iso (10 µM), Epi (10 µM), or Phe (10 µM) for 10 minutes after 
pretreatment with Tim (10 µM) for 5 minutes, if indicated.  Cells were lysed for immunoprecipitation with an anti-
flag antibody to examine the association between β2AR/arrestin complex and ERK.  D and E, WT fibroblasts 
expressing GFP-Arr3 or GFP-V54DArr2 were stimulated with Epi for 5 min before being fixed for phospho-ERK 
(ERKp) staining.  F, WT fibroblasts expressing GFP-V54DArr3 were stimulated with Epi (10 µM) for 5 min, the 
cells were then lysed and separated into nuclear and cytosolic fractions.  G, WT fibroblasts expressing GFP-
V54DArr3 were stimulated with Epi (10 µM) for the indicated times. Phospho-ERK (ERKp) was normalized against 
total ERKT. N=3. *, p<0.05; ***, p<0.001 by unpaired student t-test. 
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Figure 2.7. Recruitment of β Arrestin upon activation of the β2AR sequesters and Gq-coupled receptor 
signaling-induced ERK signal within the cytoplasm in cardiac fibroblasts. WT (A) cardiac fibroblasts or (B) 
MEFs were stimulated with Phe (10 µM), angiotensin II (1 µM), thrombin (1 nM), or PMA (10 µM), in the presence 
or absence of Iso (10 µM), for 5 minutes.  Cells were fixed and stained with anti-ERKp antibody. Alternatively, (A) 
cardiac fibroblasts expressing a dominant negative GFP-V54DArr2 or (B) MEFs lacking both Arrestin 2 and 
Arrestin 3 (Arr2/3 KO) were stimulated with Phe (10 µM), angiotensin II (1 µM), thrombin (1 nM), or PMA (10 
µM), in the presence or absence of Iso (10 µM), for 5 minutes.  Cells were fixed and stained with anti-ERKp 
antibody.  
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Figure 2.8. Model explaining the mechanism behind GPCR-mediated arrestin-dependent sequestration of 
ERK induced by another GPCR. Activation of GPCR1 (β2AR) leads to arrestin recruitment and subsequent β2AR 
internalization.  The β2AR-bound arrestin assembles a signaling complex, which recruits Gq-coupled receptor 
(GPCR2)-induced ERK.  Arrestin can potentially “prime” phosphatases (PPS) to dephosphorylate α1AR-induced 
ERK.  This arrestin-ERK complex sequesters α1AR-induced ERK within the cytoplasm and prevents nuclear 
translocation. 
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Supplementary Figure 2.I. Adrenergic receptor antagonists do not alter basal phospho-ERK levels. A, WT 
cardiac fibroblasts were treated for 5 min with 10 µM of either prazosin (Prz) or timolol (Tim) or yohimbine (Yoh).  
B, WT cardiac fibroblasts were treated for 5 min with 10 µM of either Tim, Propanolol (Pro), Alprenolol (Alp), 
Carvedilol (Carv) or PMA for 10 min.  Cells were harvested and Phospho-ERK (ERKp) and total ERK (ERKT) were 
detected with western blotting and signals were normalized as ERKp/ERKT. N=3. 
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Supplementary Figure 2.II.  Iso-induced ERK signaling is both cell- and development specific. Neonatal 
cardiac fibroblasts, HEK 293 cells, Neonatal cardiac myocytes, Adult cardiac myocytes and MEF cells were treated 
for 5 min with 10 µM of Isoproterenol (Iso) or 10 min with 10 µM PMA for 10 min.  Cells were harvested and 
Phospho-ERK (ERKp) and total ERK (ERKT) were detected with western blotting. 
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Supplementary Figure 2.III.  Neonatal Cardiac fibroblasts predominantly express α1A and α1B but not α1D 
α1AR subtypes.  RNA was extracted from neonatal cardiac fibroblasts according to protocol supplied with the 
Aurum total RNA minikit (Biorad, Hercules, CA).  cDNA was created and amplified via PCR in a one step method 
using the protocol supplied with the Access RT-PCR system (Promega, Madison, WI).  Both α1A-AR and α1B-AR, 
but not α1D-AR, were detected in neonatal cardiac fibroblasts. 
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Supplementary Figure 2.IV. ERK activation does not occur via classical Gs-PKA signaling. A, WT cardiac 
fibroblasts were pretreated, if indicated, with 200 ng of pertussis (PTX) O/N before stimulation with either 10 µM 
epinephrine or phenylephrine (Phe) for 5 min.  B, WT cardiac fibroblasts were pretreated, if indicated, with 10 µM 
H89 for 30 min before stimulation with either 10 µM epinephrine or phenylephrine (Phe) for 5 min.  Cells were 
harvested and Phospho-ERK (ERKp) and total ERK (ERKT) were detected with western blotting and signals were 
normalized as ERKp/ERKT. N=3. 
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Supplementary Figure 2.V. Co-activation of βARs prevents nuclear accumulation of ERK signal induced by 
α1ARs.  A, WT cardiac fibroblasts were stimulated with Phe (10 µM) in the presence or absence of Iso (10 µM). 
Phospho-ERK (ERKp) was detected by immunofluorescence imaging.  B, WT fibroblasts were stimulated with Phe 
(10 µM) in the presence or absence of Iso (10 µM) for 5 mins. Phospho-ERK (ERKp) and total ERK (ERKT) were 
detected with Western blotting and signals were normalized as ERKp/ERKT N=3; ***, p<0.001. 
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Supplementary Figure 2.VI.  α1ARs do not form heterodimers with β2AR.  FLAG-tagged α1A-AR, α1B-AR 
or α1D-AR constructs were transfected into MEF cells along with HA-β2AR.  After 48 hr expression, cells were 
lysed for immunoprecipitation with an anti-flag antibody to examine the association between β2AR and α1AR 
subtypes and ERK.  HA and FLAG were detected with western blotting. 
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Supplementary Figure 2.VII. Effective GRK knockdown in MEF cells.  WT MEF cells were transfected with 
shRNA constructs target at either GRK2, GRK3 or GRK5.  After expression and selection, cells were lysed and 
harvested and lysates were subjected to SDS-PAGE.  Individual GRK isoforms were visualized with Western 
blotting. 
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Supplementary Figure 2.VIII. Src is involved in βAR cross-talk with the α1AR in cardiac fibroblasts. A and 
B, WT fibroblasts expressing a dominant negative Src (HA-DN-Src) were stimulated with 10 µM Epi or Phe for the 
indicated times.  Phospho-ERK (ERKp) and total ERK (ERKT) were detected via Western blotting and signal was 
quantitated as ERKp/ERKT.  C, WT fibroblasts expressing a dominant negative Src (HA-DN-Src) were stimulated 
with Epi for the indicated times.  Cells were lysed and separated into nuclear and cytosolic fractions.  Phospho-ERK 
(ERKp) and total ERK (ERKT) in each fraction were detected via Western blotting and signal was quantitated as 
ERKp/ERKT N= 4. *, p<0.05; ***, p<0.001. 
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Supplementary Figure 2.IX. β2AR, Arrestin 3 and ERKp colocalize intracellularly upon Epi stimulation.  
DKO MEF cells were cotransfected with FLAG-β2AR and GFP-Arr3 constructs.  Cells were then stimulated for 10 
min with Epi (10 µM), then fixed and stained with either a FLAG or anti-ERKp antibody. 
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Chapter 3:  
Receptor tyrosine kinases partner with GPCRs to tune mitogen dose-
dependent cell proliferation  
Abstract 
 Receptor tyrosine kinases (RTKs) and G-protein coupled receptors(1) are two major 
families of cell surface receptors that are capable of eliciting mitogenic signaling in response to 
extracellular stimuli. Here, we characterize a novel signaling complex of mitogen-activated 
insulin receptor and the sympathetic activity-regulated β2 adrenergic receptor (β2AR) that fine-
tunes insulin dose-dependent subcellular activation of mitogen-activated protein kinase (MAPK) 
for cell proliferation. Low concentrations of insulin lead to the classic shc/grb2 pathway for 
activation and nuclear translocation of ERK, and cellular proliferation. Interestingly, increasing 
concentrations of insulin switch to a β2AR-dependent pathway via an IR-IRS2-G-protein 
receptor kinase 2 (GRK2) cascade for phosphorylation and transactivation of the β2AR. The 
phosphorylated β2AR then activates β arrestin 2 for the GPCR internalization and activation of 
MAPK in the cytoplasm, which attenuates IR-mediated cellular proliferation. Moreover, insulin-
like growth factor receptor, but not other RTKs share the same signaling mechanism with IR. 
Co-stimulation of β2AR and IR sequesters ERK signal in the cytoplasm induced by low 
concentrations of mitogen, and prevents IR-induced cell proliferation and IGF-1-induced 
embryonic stem cell self-renewal. This elaborate, dynamic, and mitogen dose-dependent 
activation of the IR/β2AR complex represents a new paradigm in RTK signaling and provides a 
mechanism for modulation of RTK-dependent cell proliferation by the sympathetic nervous 
system. 
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Introduction  
 Understanding how cells integrate information from a variety of chemically diverse 
signals into complex orchestrated responses such as cell proliferation, differentiation, and 
apoptosis is an overarching goal of cell biology.  Receptor tyrosine kinases (RTKs) and G 
protein-coupled receptors (GPCRs) represent two major families of cell surface receptors to 
transduce extracellular stimuliand induce heterologous signal transduction pathways leading to 
divergent and even opposing cellular processes in cells.  Although insulin receptor (IR) and β2 
adrenergic receptor (β2AR) elicit distinct cellular signaling pathways via independent 
mechanisms, they are involved in overlapping physiological functions by targeting to the same 
cells in tissues like fat, liver, skeletal muscles, and cardiac muscles. Extensive studies show that 
insulin and adrenergic activation not only share many components in the intracellular signaling 
pathways(2-8), but also act reciprocally to blunt each other’s signaling in adipocytes and liver 
cells(9-16). However, the mechanism underlying the coordination and integration of IR and β2AR 
signaling remains poorly understood. 
 IR, a member of the large RTK family, induces activation of both mitogen-activated 
protein kinases (MAPKs) and Akt. Activation of Akt is dependent on recruitment and 
phosphorylation of insulin receptor substrate(17) and activation of PDK and PI3K. Akt regulates 
glucose uptake, cell survival, and protein synthesis(18-20). In parallel, IR activation induces 
Shc/grb2-mediated ERK activity leading to cellular hypertrophy, proliferation, and survival(21-24).  
Conversely, ligand binding to β2AR, a member of the GPCR superfamily, leads to G protein 
activation, which induces production of second messengers like cAMP for activation of 
downstream kinase protein kinase A (PKA). The activation of PKA leads to a wide range of 
stress responses including muscle contraction and relaxation(25), neuron excitation(26-28), and 
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secretion(29). In addition to G protein signaling, β2AR stimulation is also implicated in mitogenic 
signaling via an arrestin-dependent mechanism(30, 31). 
 Extensive studies show that insulin and adrenergic activation also act reciprocally to 
blunt each other’s signaling in adipocytes and liver cells. In adipocytes, IR activation leads to 
increased βAR down-regulation via phosphorylation of the β2AR(9-14). Meanwhile, insulin-like 
growth factor 1 (IGF-1) induces PI3K/AKT-dependent phosphorylation of β1AR for 
internalization in CHO cells(32). On the contrary, chronic stimulation of βAR impairs insulin 
signaling-induced Akt activation and translocation of glucose transporter 4 (Glut4), as well as 
glucose uptake in adipocytes and cardiac myocytes(16, 33).  
 Meanwhile, numerous studies indicate potential coordination of signaling processes 
between IR and βAR. Recent studies suggest βARs transactivate a growing list of RTKs 
including the epidermal growth factor receptor(34-36), platelet-derived growth factor receptor(37, 
38), and insulin-like growth factor receptor(11, 39).   Alternatively, proteins in βAR signaling 
pathways also participate in RTK signaling cascades.   For example, knockdown of Gαi2 in 
adipose and liver tissue with antisense oligos impairs insulin function, induces hyperinsulinemia, 
impaired glucose tolerance, and insulin resistance in vivo(2). Furthermore, IGF-1-mediated 
MAPK phosphorylation is dependent on Gαi/βγ signaling(3, 40) or β arrestin 1 activation(41-43). 
Moreover, GRKs(4, 5) and the scaffold/adaptor protein β arrestin(6-8) regulate insulin-induced and 
GLUT4 dependent glucose uptake.  
 Due to the high number of parallels between IR and βAR signaling involving common 
intermediate signaling proteins as well as reciprocal antagonized effects on individual pathways, 
we envision the potential for RTK-GPCR cross talk via integrated signaling complexes to 
coordinate efficiency and specificity of signaling for divergent cellular responses.   Here we have 
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characterized novel signaling machinery in which IR and β2AR form a complex to fine-tune 
subcellular activation of IR-induced mitogenic signaling. Stimulation of IR leads to IRS2-
mediated GRK recruitment that is capable of phosphorylating the β2AR leading to β arrestin 2-
mediated β2AR internalization. The activation of β2AR/β arrestin 2 is necessary to promote full 
activation of mitogenic signaling, which is also sequestered in the cytoplasm. In contrast the 
classic mitogenic signaling induced by IR via Shc/Grb2 activation is small, and enriched in the 
nucleus. IR activates these two distinct pathways in an insulin dose-dependent fashion, through 
which low concentration promotes the classic pathway and cell proliferation, whereas high 
concentration leads to transactivation of β2AR-dependent mitogenic activity. Moreover, we show 
that only IR and IGF-R utilize β2AR to induce mitogenic signaling whereas other RTKs do not. 
Co-stimulation of β2AR convertsthe classic nuclear mitogenic signaling into a β2AR-dependent 
cytoplasmic signaling, and blocks insulin-induced cell proliferation and Insulin-like Growth 
Factor (IGF-1)-induced mouse embryonic stem cell self-renewal. The discovery that RTKs 
utilize GPCR machinery to induce subcellular activation of mitogenic signaling in a mitogen 
dose-dependent fashion is a novel paradigm in RTK signal transduction, presenting a new facet 
of RTK signaling.  Our results also underscore the critical role of signaling cross talk and 
integration between RTKs and GPCRs in vivo.  
 
Materials & Methods 
Cell culture, transfection, and adenoviral infections  
 Animal protocols were approved by the IACUC of the University of Illinois according to 
NIH regulation.   H9C2 rat myoblast cell lines were obtained from ATCC.   Mouse Embryonic 
Fibroblasts (MEFs) were isolated from the embryos of wild-type, β1AR knock-out (KO), β2AR 
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KO or β1/β2AR DKO FVB mice.   MEFs from β-arrestin 1 KO, β arrestin 2 KO, and β arrestin 
1/β arrestin 2 DKO mice were donated by Dr. Robert Lefkowitz (Duke University). MEFs from 
Gi1 KO, Gi2 KO, Gi3 KO mice were described else where(44).  MEFs from IRS1 KO, IRS2 KO 
or IRS1/2 DKO mice were gifts from Dr. Morris White (Harvard University).  
 Cells were cultured in T75 tissue culture treated flasks until 90% confluent.  Cells were 
then plated on 35 mm or 10 cm tissue culture treated dishes at a confluency of 60-70%.  MEFs 
were maintained for 24h in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum and experiments were performed, unless otherwise noted, on cells serum-deprived 
for 24h.  H9C2 cardiac myoblasts were cultured in T75 tissue culture treated flasks until 90% 
confluent.  Cells were then plated on 35 mm or 10 cm tissue culture treated dishes at a 
confluency of 60-70%.  H9C2 myoblasts were maintained for 24h in DMEM (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum and experiments were performed, 
unless otherwise noted, on cells serum-deprived for at least 3h. 
 MEFs or H9C2 cardiac myoblasts were infected with recombinant adenoviruses or 
transfected, as indicated, after being cultured for 24h.  Recombinant plasmids expressing 
βARKct, GFP- β arrestin 2, and GFP- β arrestin 2 V54D were generated as previously 
described(1).  GFP- β-arrestin 2 and GFP- β arrestin 2 V54D plasmids were gifts from Dr. Gang 
Pei (Chinese Academy of Sciences, Shanghai).  Plasmids containing HA-tagged GRK2 mutants 
lacking the Pleckstrin homology domain (∆PH) or the kinase domain (∆Kinase) were constructed 
in pcDNA3 (Invitrogen, CA).  Experiments were conducted after 48h expression. 
Drug Treatment  
 Cells were treated with the following agonists or antagonists at the indicated dosage and 
times: the IR agonist insulin (Sigma, St. Louis, MO), the βAR agonist isoproterenol (Sigma, St. 
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Louis, MO), the α1AR agonist phenylephrine (Sigma, St. Louis, MO), the PKC stimulator 
phorbol 12-myristate 13-acetate (PMA; Sigma, St. Louis, MO), insulin-like growth factor 1 
(IGF; Sigma, St. Louis, MO), epidermal growth factor (EGF; Sigma, St. Louis, MO), platelet-
derived growth factor (PDGF; Peprotech, Rocky Hill, NJ), fibroblast growth factor (FGF; Sigma, 
St. Louis, MO) or nerve growth factor (NGF; Sigma, St. Louis, MO).  Cells were treated with the 
following inhibitors as indicated: an AKT inhibitor LY294002 (Sigma, St. Louis, MO), a 
Shc/Grb2 inhibitor actinomycin D (Sigma, St. Louis, MO), a Gi specific inhibitor pertussis toxin 
(PTX; Sigma, St. Louis, MO), a non-specific phospholipase C (PLC) inhibitor U73122 
(Calbiochem, San Diego, CA), a PKA inhibitor N-[2-(p-Bromocinnamylamino) ethyl]-5-
isoquinolinesulfonamide dihydrochloride (H89; Sigma, St. Louis, MO), a PKC inhibitor 
calphostin C (Calbiochem, San Diego, CA), or a MEK inhibitor U1026 (Sigma, St. Louis, MO). 
Immunoblotting  
 Unless specifically noted, all antibodies were purchased from Santa Cruz (Santa Cruz, 
CA).  Antibodies specific to both phosphorylated and total ERK1/2 were purchased from Cell 
Signaling (Danvers, MA).  Cells were serum-starved for 24h prior to the addition of the agonist 
or antagonist as indicated.  Alternatively, cells were pretreated with inhibitors as indicated in the 
figure legends.  After stimulation, cells were chilled, washed, and harvested in lysis buffer (5 
mM Tris-HCl pH 7.4, 1 mM EDTA, 1% NP-40, and Halt Protease/Phosphatase Inhibitor 
Cocktail from (Thermo Scientific, IL).  Lysates were clarified and resolved on 10% SDS-PAGE 
gels for Western blot.  Phosphorylated and total ERK were detected via incubation with the 
corresponding antibodies at 1:1000 for 2h RT.  Other antibodies were used at 1:800 for 2h at RT 
unless otherwise noted.  Primary antibodies were visualized with IRDye 680CW goat anti-mouse 
or with IRDye 800CW goat anti-rabbit secondary antibodies using an Odyssey scanner 
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(1:10,000; LI-COR Biosciences, Lincoln, NE).  Phospho-ERK signals were corrected for total 
ERK levels and plotted as increase over basal levels. Alternatively, S355/S356 phosphorylation 
levels were corrected against γ-tubulin levels and plotted as arbitrary units (AU).  Signal 
intensity was quantitated by densitometry of Western blots. 
Immunofluorescence microscopy  
 Fluorescent images were taken with a Zeiss Axioplan 2 microscope (Carl Zeiss Inc., 
Thornwood, NY) with an attached CCD camera and Metamorph software (Molecular Devices, 
Sunnyvale, CA).  Cells were plated on laminin-coated coverslips and then serum starved for 24h. 
Cells were then stimulated as indicated and then fixed with 4% paraformaldehyde for 1h at 4oC.  
Cells were then permeabilized with PBST (0.1% Triton X-100 in PBS) for 15 min at RT, rinsed 
and blocked, and then incubated with 1:400 IR antibody, 1:400 β2AR antibody, or 1:400 ERKP 
antibody diluted in blocking buffer (PBST with 10% FBS) for 2h at RT. AlexaFluor 594-
conjugated goat anti-mouse IgG1 antibody, AlexaFluor 488-conjugated goat anti-rabbit IgG1, or 
AlexaFluor 350-conjugated goat anti-rabbit IgG1 antibodies were utilized as the secondary 
antibody diluted to 1:1000 in blocking buffer for 1h at RT.  Alternatively, cells were infected 
with recombinant plasmids expressing GFP- β-arrestin 2 to allow visualization. 
Co-immunoprecipitation  
 Wild-type H9C2, WT MEF, and IRS2 KO MEF cells were utilized for co-
immunoprecipitation. WT H9C2 cells were infected with both FLAG-tagged mouse β2AR and 
GFP- β arrestin 2 before the procedure.  Cells were stimulated with the indicated agonist for 10 
min before being lysed with lysis buffer.  Lysates were cleared by centrifugation and subjected to 
immunoprecipitation with either M2 anti-FLAG affinity resin (Sigma, St. Louis, MO) or Protein 
A beads (Pierce, Rockford, IL) coated with IR IRS2 or GRK2 antibodies. The 
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immunoprecipitates were resolved via SDS-PAGE and blotted with antibodies against IR 
(1:500), β2AR (1:500), β arrestin 2 (1:500), IRS2 (1:500), GRK2 (1:1000), GRK3 (1:1000), HA 
(1:500), GFP (1:1000) or Gi (1:500).  Primary antibodies were visualized with IRDye 680CW 
goat anti-mouse or with IRDye 800CW goat anti-rabbit secondary antibodies using an Odyssey 
scanner (LI-COR Biosciences, Lincoln, NE). 
Cell Proliferation and sizing assays  
 WT, β1AR KO or β2AR KO MEF or H9C2 rat myoblast cells were stimulated with the 
indicated agonist or antagonist for 48h; cells were then lysed and harvested.   Total protein 
concentration was measured via BCA assay. Colorimetric analysis was performed with a 
Spectramax M2 fluorometer reader (Molecular Devices, Sunnyvale, CA). The data were 
normalized against the control.  Alternatively, protein levels were quantitated by Western 
blotting against γ-tubulin (1:2000).   For cell counting assays, H9C2 cardiac myoblasts were 
stimulated with the indicated agonist or antagonist for 48h.  Pictures were taken with a Zeiss 
Axioplan 2 microscope (Carl Zeiss Inc., Thornwood, NY) with an attached CCD camera and 
Metamorph software (Molecular Devices, Sunnyvale, CA).   Cells were then counted in a 
blinded manner.  The cell proliferation ELISA was carried out utilizing BrdU Labeling and 
Detection Kit III (Roche, Basel, Switzerland) according to the manufacturer’s instructions.   
Cells were cultured in a 96-well plate as described above and left overnight to attach.  10 μM 
BrdU was added to cells prior to drug stimulation for 24h at 37oC.  Cells were then fixed and 
nucleases were allowed to partially digest cellular DNA.  Cells were then incubated with an anti-
BrdU antibody (200 mU/ml) for 30 min at 37oC.  Colorimetric analysis was performed with a 
Spectramax M2 fluorometer reader. The data were normalized against the control.  
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GRK and IR Knockdown 
 GRK2, GRK3, GRK5, and GRK6 mouse shRNA plasmids (Sigma, St. Louis, MO) were 
used to create recombinant lentiviruses.  WT MEF cells were infected with GRK shRNA 
lentiviruses.  After overnight infection and additional 24h expression, 10 μg/ml of puromycin 
were added to the dishes to select for positive infection. After 48h puromycin selection, cells 
were serum starved for another 24h. Cells were then harvested as described above for Western 
blot.  Cell lysates were resolved via SDS-PAGE and blotted with antibodies against GRK2, 
GRK3, GRK5, or GRK6 (1:1000). Primary antibodies were visualized with IRDye 680CW goat 
anti-mouse or with IRDye 800CW goat anti-rabbit secondary antibodies using an Odyssey 
scanner (LI-COR Biosciences, Lincoln, NE).  Alternatively, siRNA oligos targeting the mouse 
insulin receptor (Integrated DNA Technologies, Coralville, IA) were transfected into WT MEF 
cells and experiments were conducted after 48h expression.   
Statistical analysis  
 Data analysis was performed using GraphPad Prism version 4.0 (GraphPad Software, San 
Diego, CA). 
 
Results 
β2AR modulates IR-induced ERK signaling at high insulin concentrations 
 Both IRs and βARs are implicated in promoting ERK activation via distinct signaling 
mechanisms(24, 30, 31).  Utilizing MEFs and H9C2 cardiac myoblast cells, we investigated the 
mechanism leading to the modulation of ERK signaling upon potential cross talk between the IR 
and the βARs.  We examined agonist-dependent ERK phosphorylation induced by insulin.  
Insulin stimulation potently activated ERK in a dose-dependent manner (Fig 3.1A) with 
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phosphorylation levels peaking at 10 min (Fig 3.1B). Further, the localization of phospho ERK 
was also dose-dependent, switching from the nucleus to the cytoplasm at increasing 
concentration of insulin (Fig 3.1C).  Surprisingly, deletion of the β2AR, but not the β1AR 
significantly reduced insulin-induced ERK signaling (Figs 3.1D and 3.1E) while leaving insulin-
induced AKT signaling intact (Supplementary Figure 3.I).  Previous studies have shown that 
β2AR activation is sufficient to sequester ERK signaling in the cytoplasm(1).  We found that 
stimulation with higher concentrations of insulin (100 nM) resulted in nuclear accumulation of 
ERK signaling in the absence of the β2AR (Fig 3.1E).  In contrast, at low concentrations of 
insulin (10 nM), phospho-ERK translocated to the nucleus in the presence or absence of the 
β2ARs (Fig 3.1E).  Moreover, insulin induced ERK activity is dependent on the IR (Fig 3.1F).  
Together, these results suggest that β2AR was necessary for ERK activation and cytoplasmic 
sequestration in response to IR stimulation.  Interestingly, this cross talk occurred in the presence 
of inhibition of classical β2AR signaling pathways (Supplementary Figure 3.II).  Further, 
alterations in ERK signaling were not due to altered protein expression of IR and β2AR signaling 
components in MEF cells lacking adrenergic receptors (Supplementary Figure 3.III).   Thus, 
while insulin-induced ERK signaling is dependent on β2AR expression, β2AR expression alters 
the spatial ERK signaling profile in an insulin dose-dependent fashion.    
Cross talk with the β2AR is a significant pathway contributing to IR-mediated ERK 
signaling 
 Classically, ERK signaling originating from the IR occurs though the 
shc/grb2/SOS/ras/raf/MEK axis(24).  We observed the existence of two signaling pathways—one, 
β2AR-independent pathway, activated in response to low insulin concentrations and the other, 
β2AR-dependent pathway, activated upon high insulin concentrations. We then set to define 
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these two independent signaling pathways.  Inhibition of shc/grb2 with actinomycin D slightly 
reduced ERK activation upon stimulation with 100 nM insulin (Figs 3.2A and 3.2D), but 
completely prevented ERK activation upon stimulation with 10 nM insulin (Figs 3.2B and 3.2D). 
Moreover, actinomycin did not alter the subcellular ERK localization upon stimulation with 100 
nM insulin (Fig 3.2D).  However, upon deletion of βARs, inhibition of the shc/grb2 interaction 
with actinomycin D prevented ERK activation with either 100 nM or 10 nM insulin stimulation 
(Figs 3.2C and 3.2D).  Together, these results confirm that, at low insulin concentrations, ERK 
activation originating from the IR occurs though the classical shc/grb2/SOS/ras/raf/MEK axis 
leading to nuclear ERK translocation. Alternatively, upon stimulation with 100 nM insulin, a 
separate and β2AR-dependent pathway is activated to promote full activation of ERK that is also 
sequestrated in cytoplasm.     
β2AR-dependent cytoplasmic sequestration of insulin-induced mitogenic signaling occurs 
via β2AR/β arrestin 2 scaffold formation.   
 Activation of β2AR stimulation induces ERK signal via a β arrestin 2-mediated formation 
of β2AR/β arrestin 2/ERK scaffold
(30, 31).  We sought to determine whether insulin stimulation 
induces arrestin-mediated ERK activation though this pathway.  Upon 100 nM insulin 
stimulation, MEFs lacking β arrestin 2 displayed decreased ERK activation overall, which 
localized within the nucleus (Figs 3.3A and 3.3B).  Conversely, cells containing β arrestin 2 
displayed robust ERK activation that was localized in the cytoplasm (Figs 3.3A and 3.3B).  To 
confirm the role of β arrestin 2 in insulin-mediated ERK activation, we introduced a dominant-
negative β arrestin 2 mutant (β arrestin 2 V54D).  Addition of this mutant significantly reduced 
ERK activation upon 100 nM insulin stimulation (Fig 3.3C).  Previous studies indicate that IR 
can interact with β arrestins in adipocytes(45). The involvement of the β2AR as well as β arrestin 2 
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in insulin-induced ERK activation suggests that the IR and β2AR may interact on the cell 
membrane.  To confirm this, we examined the association between IR, β2AR and β arrestin 2 
upon 100 nM insulin stimulation.  At basal conditions IR associated with β2AR and β arrestin 2 
(Fig 3.3D).  Conversely, β2AR did not interact with β arrestin 2 (Fig 3.3D).  Upon stimulation, 
however, IR lost its interaction with both β2AR and β arrestin 2 while β2AR became associated 
with β arrestin 2 (Fig 3.3D).  Furthermore, β2AR/β arrestin 2/ERK colocalized upon insulin 
stimulation in a punctate pattern, suggesting arrestin-mediated β2AR internalization and 
formation of a β2AR/β arrestin 2/ERK complex leading to cytoplasmic sequestration of ERK 
signaling (Fig 3.3E).  Together, our data suggest that insulin stimulates β arrestin 2-mediated 
β2AR internalization and formation of a β2AR/β arrestin 2/ERK complex within the cytoplasm. 
GRK2-mediated β2AR phosphorylation is required for insulin-induced ERK activity 
 Because IR/β2AR cross talk occurs despite classical β2AR signaling component inhibition 
(Supplementary Figure 3.II), we suspected non-traditional β2AR signaling.  GRK 
phosphorylation of the β2AR at serines 355 and 356 is a well-defined mechanism leading to β 
arrestin 2-mediated receptor internalization and initiation of ERK activation(30).  We 
hypothesized that IR recruits GRK to phosphorylate the β2AR leading to β arrestin 2-mediated 
initiation of the ERK signaling cascade.  Selective knockdown of GRK2, but not other GRKs in 
MEF cells significantly attenuated ERK activation in response to 100 nM insulin stimulation 
(Fig 3.4A and Supplementary Figure 3.IV).  In addition, transfection of WT β2AR, but not a 
mutant β2AR lacking the GRK2 phosphorylation sites, was able to recover insulin-induced ERK 
signaling in β2AR KO MEF cells (Fig 3.4B).  To examine whether insulin stimulation leads to 
GRK2-mediated β2AR phosphorylation, we examined S355/S356 phosphorylation of the β2AR 
in response to insulin stimulation.  Insulin stimulation led to a time-dependent GRK-mediated 
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phosphorylation of the β2AR (Fig 3.4C). β2AR phosphorylation also displayed a biphasic 
increase in an insulin-dose dependent fahsion with second phase beginning at 100 nM insulin 
stimulation (Fig 3.4D).  These data suggest the presence of two independent signaling pathways 
existing—the shc/grb2-dependent pathway that is activated upon stimulation with low 
concentrations of insulin and the β2AR-dependent pathway that is only activated upon high 
insulin stimulation.  To confirm that phosphorylation of the β2AR at serines 355 and 356 is 
dependent on GRK2, we utilized a well-characterized GRK2 inhibitor (βARKct) and examined 
S355/S356 phosphorylation upon 100 nM insulin stimulation.  We found that inhibition of 
GRK2 with βARKct significantly reduced S355/S356 phosphorylation (Fig 3.4E).  Together, 
these results confirm our hypothesis that β2AR phosphorylation of S355/S356 results from IR-
mediated GRK2 recruitment and that this phosphorylation is necessary for β arrestin 2 
recruitment to the β2AR and for ERK activation.  
IRS2 recruits GRK2 to the IR allowing β2AR phosphorylation 
 The IR is capable of utilizing both Gi proteins(4) and IRS proteins(5) to recruit GRK 
proteins.  In order to determine the mechanism by which IR recruits GRK2 to phosphorylate the 
β2AR, we examined ERK activation in both IRS KO and Gi KO MEF cells.  Interestingly, 
deletion of Gi proteins had no effect on overall ERK activation upon insulin stimulation 
(Supplementary Figure 3.V).  Conversely, deletion of IRS2, but not IRS1, significantly 
attenuated ERK activation upon 100 nM insulin stimulation (Fig 3.5A).  In addition, deletion of 
IRS2 prevented β2AR phosphorylation at S355/S356 (Fig 3.5B).  To further confirm the role of 
IRS2 in scaffolding GRK2 to the IR, Co-IP experiments showed an increased GRK2/IR/IRS2 
tertiary interaction upon insulin stimulation (Figs 3.5C and 3.5D).  As predicted, Gi did not 
associate with this complex.  In accordance, deletion of IRS2 prevented GRK2 interaction with 
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IR both in the presence and absence of insulin stimulation (Fig 3.5E).  Together, these data show 
that IRS2 is important in recruiting GRK2 to the IR.   
The C-terminal Pleckstrin Homology domain of GRK2 is essential in recruiting GRK2 to 
IRS2 
 Although IRS proteins have been shown to recruit GRK proteins, the exact region of 
GRK2 necessary for interaction with IRS2 is unknown.  In order to investigate this we utilized 
the following mutant GRK2 proteins: a mutant GRK2 lacking both the N terminal RGS 
homology(46) domain and the central kinase domain (βARKct), a mutant GRK2 lacking the 
kinase domain and the C terminal Pleckstrin homology (PH) domain (∆ kinase), or a mutant 
GRK2 with an N terminal RH domain deletion (∆ RH).  Mutant constructs containing the C 
terminal PH domain significantly attenuated ERK activation upon insulin stimulation, suggesting 
competitive inhibition of WT GRK2 binding to IRS2 (Fig 3.6A).  To confirm the domain of 
GRK2 necessary for IRS2 interaction, we transfected MEF cells with WT GRK2 or either the 
mutants (βARKct, ∆ RH, or ∆ kinase). IRS2 was then immunoprecipitated to examine which 
mutants were capable of binding IRS2.  We found that only mutant GRK2 constructs containing 
the C terminal PH domain (βARKct and ∆ RH) were capable of binding IRS2 (Fig 3.6B).  
Together, these results confirm that the C terminal PH domain of GRK2 is necessary for 
recruitment of GRK2 to IRS2 and ERK activation. 
β2AR cross talk is a universal mechanism regulating RTK-mediated ERK activation for 
cell proliferation 
 Due to the similarities among different RTK signaling pathways, we examined the 
potential cross talk with the β2ARs by different RTK-mediated ERK activation.  Surprisingly, 
β2AR deletion only attenuated insulin- and IGF-1-mediated ERK activation while stimulation 
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with other growth factors including EGF, FGF and PDGF was unaffected by β2AR deletion (Fig 
3.7).  Therefore, the cross talk with the β2AR is specific to members of the class II RTKs, 
including the IR and Insulin-like Growth Factor receptor (IGFR). 
 Studies have indicated that the localization of ERK within a cell determine the 
physiological outcome of signaling.  We examined cellular proliferation upon IR/β2AR cross 
talk.  We found that stimulation of H9C2 with 10 nM insulin promoted an increase in protein 
synthesis (Fig 3.8A), cell proliferation (Fig 3.8B) as well as BrdU incorporation (Fig 3.8C) 
which was attenuated by ERK inhibition (Figs 3.8A-3.8C).  Furthermore, we found that β2AR 
deletion enhances MEF protein content (Fig 3.8D) as well as BrdU incorporation (Fig 3.8E) 
upon stimulation with 100 nM insulin.  Interestingly, 10 nM insulin treatment for 48h stimulated 
significantly more protein production (Fig 3.8F), cell proliferation (Fig 3.8G) and BrdU 
incorporation (Fig 3.8H) than 100 nM insulin treatment.  The increased protein production upon 
100 nM insulin stimulation, however, was not due to cell proliferation, suggesting cellular 
hypertrophy (Fig 3.8I).  Together, these results suggest that nuclear translocation of ERK is 
necessary for cellular proliferation in both H9C2 cells as well as MEF cells. 
Stimulation of β2AR prevents cell proliferation by redistributing cellular ERK induced by 
mitogen stimulation 
 Previously we have shown that β2AR stimulation is capable of sequestering ERK 
signaling originating from other GPCRs via β2AR/β arrestin 2/ERK complex formation(1).  We 
found that β2AR stimulation with isoproterenol prevented nuclear translocation of IR-induced 
ERK upon 10 nM insulin stimulation (Fig 3.9A).  Accordingly, isoproterenol pretreatment 
significantly reduced H9C2 protein synthesis (Fig 3.9B), cell proliferation (Fig 3.9C), and BrdU 
incorporation (Fig 3.9D).  In addition, isoproterenol pretreatment attenuated insulin-induced 
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protein production, cellular proliferation, as well as BrdU incorporation in WT MEF cells (Figs 
3.9E-3.9G).  As expected, β2AR deletion prevented isoproterenol-induced attenuation of protein 
production, cellular proliferation, and BrdU incorporation under insulin sitmulation (Figs 3.9E-
3.9G).  In order to determine whether βAR stimulation-induced attenuation of RTK-induced cell 
proliferation is a universal mechanism, we examined the proliferation of mouse embryonic stem 
cells (mESCs).  Interestingly, we found that βAR stimulation attenuated IGF1-induced mESC 
protein synthesis (Fig 3.9H) and BrdU incorporation (Fig 3.9I) as well as cell proliferation 
(Supplementary Figure 3.VI).  Together, these results confirm that β2AR stimulation is capable 
of attenuating mitogen-induced H9C2, MEF and mESC proliferation. 
 
Discussion 
 In this study, we have identified a novel mechanism regulating IR-induced ERK MAPK 
signaling with a preassembled IR/β2AR complex (Fig 3.10).  This is in contrast to the classic 
shc/grb2/SOS/ras/raf/MEK/ERK axis, which is activated at low concentrations of insulin to 
induce a nuclear ERK signal for gene expression. Here, we characterize an alternative, 
grb2/SOS-independent pathway(47) that is activated at high concentration of insulin. Activation of 
IR leads to IRS2-mediated GRK2 recruitment to the preassembled IR/β2AR signaling complex, 
and promotes β2AR phosphorylation on the cytoplasmic carboxyl terminus at serines 355 and 
356.  Upon GRK-mediated phosphorylation, β2AR recruits β arrestin 2 for receptor 
internalization. The activated β2AR/β arrestin 2 complex promotes full activation of ERK that is 
sequestered within the cytoplasm. This is the first evidence suggesting that an RTK can utilize a 
GPCR machinery to not only stimulate mitogenic signaling but also dictate the spatial profile of 
the signal.   
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 Emerging evidence reveals that RTKs and GPCRs cross-communicate with each other, in 
particular, a growing list of GPCRs show capability in transactivation of RTKs(11, 34-39). The full 
potential of this receptor cross talk on cellular physiology has not yet been realized.  Similarly, a 
growing list of signal proteins which classically function in GPCR signaling pathways have been 
implicated in RTK signaling cascades, including G proteins(2, 3, 40, 48), GRKs(4, 5) and β arrestins(6-
8, 41-43, 49).  For example, expression of a constitutively active Gαi2 (Q205L) promotes glucose 
transport and translocation of GLUT4 to the plasma membrane upon insulin stimulation(48). IRs 
have also been shown to recruit GRKs(4, 5) and the scaffold/adaptor protein β arrestins(6-8) to 
regulate the GLUT4 dependent glucose uptake.  Furthermore, down-regulation of β arrestin 1 by 
insulin treatment impairs MAP kinase signaling by both GPCRs and RTKs(49). Meanwhile, 
numerous studies have shown that IR activation leads to βAR phosphorylation(9-11, 13, 14, 39). The 
intimate relationship between IR and βAR prompts the search of an integrated machinery to 
coordinate activation of an array of different signaling pathways. One could speculate that IR 
and βAR function in a signalosome, like many receptor-receptor interactions(9-14, 32, 50). In 
supporting this notion, we find that IR and β2AR are preassembled into a complex on the plasma 
membrane in non-stimulated cells, consistent with the proximal membrane distribution of both 
the insulin receptor(51) and β2AR(52) in lipid rafts.   
 Mechanistically, upon stimulation with insulin at high concentrations, IR leads to IRS2-
dependent recruitment of GRK2, which is different from the previously reported G protein-
dependent recruitment of GRK2(4), but is consistent with recently reported interaction between 
IRS1 and GRK2 in cardiac myocytes(5). The recruited GRK2 promotes phosphorylation of the 
β2AR at serines 355 and 356 in the IR-β2AR complexes; and this GRK2 could also potentially 
phosphorylate IRS2 for attenuation of insulin signaling(5). The phosphorylated β2AR recruits β 
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arrestin 2 for receptor internalization. Interestingly, IR also associates with β arrestin 2 at basal 
conditions (Fig 3.3 and(45)).  Upon stimulation, however, IR dissociates from both β2AR and β 
arrestin 2, probably for further attenuation of insulin stimulated IR signaling. Thus, while the 
bound β2AR/β arrestin 2 complexes undergo internalization, the dissociated IRs either remains at 
the cell surface or undergo internalization via different pathway(53).  In addition, several other 
residues on the carboxyl terminus of the β2AR have also been characterized as substrates for 
insulin-induced PI3K/AKT activity(13), as well as IR tyrosine kinase and Src activities(14, 50), 
which could also contribute to receptor internalization. The activated β2AR/β arrestin 2 complex 
is required for full increase of ERK activities under insulin stimulation, similar to the role of 
β2AR/β arrestin 2 complex in promoting ERK activation under β2AR stimulation(30, 31). 
Furthermore, β arrestin 2 scaffold formation offers a unique mechanism of regulating ERK 
signaling by facilitating activation and cytoplasmic retention(42, 54), thus decreasing transcription 
in the nucleus(55).  
 Thus, stimulation of IR with insulin is capable of activating two alternate mitogenic 
signaling pathways for distinct subcellular distribution and cellular responses.  The first pathway, 
activated by the classical Shc/Grb2/SOS/Ras/Raf/MEK axis(24), is stimulated at low insulin 
concentrations (≤10 nM).  Activation of this pathway leads to nuclear translocation of ERK and 
promotes cellular proliferation via activation of transcription factors including Elk-1(56) and 
GATA-4(57).  The second pathway, activated by higher insulin concentrations, requires β2AR 
expression for formation of the activated β2AR/β arrestin 2 scaffold to promote full ERK 
activation. Activation of this second pathway prevents nuclear accumulation of ERK and 
attenuates cellular proliferation.  Deletion of either β2AR or β arrestin 2 significantly reduced the 
insulin-induced ERK activities, and allows nuclear ERK translocation and promotes cellular 
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proliferation. While nuclear targeting of ERK is necessary for transcription(55), cytoplasmic 
retention may allow targeting to non-nuclear ERK substrates involved in different cellular stress 
processes(58), receptor desensitization(59) and protein synthesis (Fig 3.8 and (55)).  
 Interestingly, we observe that nuclear translocation of ERK upon low dose insulin 
stimulation does not occur upon concomitant β2AR stimulation. This is consistent with 
observations that the β2AR/β arrestin 2 scaffold is capable of sequestering ERK activated by 
other GPCRs.  This sequestration attenuates cellular proliferation(1), and β arrestin-mediated 
ERK retention within the cytoplasm prevents ERK-mediated transcription(55).  As a result, β2AR 
stimulation prevents insulin-induced cell proliferation as well as protein synthesis. Considering 
the ability of numerous RTKs to recruit β arrestins(6-8, 41-43, 49), our data suggest a general 
mechanism of β arrestin 2-mediated βAR modulation of mitogenic signaling upon RTK 
activation with broad implications in physiological responses upon hormonal regulation in vivo.  
It also underscores the potent inhibitory effects of adrenergic signaling on tissue development 
and regeneration.  Surprisingly, β2AR deletion only attenuated insulin- and IGF-1-mediated ERK 
activation while stimulation with other RTK ligands including EGF, FGF, and PDGF was 
unaffected by β2AR deletion.  Thus, the cross talk with the β2AR seems to be specific to class II 
RTKs, including IR and IGFR. Accordingly, concomitant βAR stimulation attenuates IGF-1 
mediated self-renewal of mouse embryonic stem cells, indicating that βAR-mediated attenuation 
of class II RTK-induced cellular proliferation is universal mechanism.  
 In summary, we have characterized a novel mechanism in which IR is capable of 
transactivating the β2AR via GRK phosphorylation leading to β arrestin 2-dependent activation 
and modulation of IR induced mitogenic signaling.  RTKs utilization of a GPCR machinery to 
induce subcellular activation of mitogenic signaling presents a novel paradigm in RTK signal 
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transduction. Our data also provide the first evidence showing that β arrestin 2 acts as a 
coordinator to integrate subcellular mitogenic signals between two major cell surface receptors, 
RTKs and GPCRs, underscoring the critical role of signaling cross talk among GPCRs and RTKs 
in vivo. 
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Figures & Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. β2AR is required for fine-tuning IR-induced subcellular ERK signaling A, WT MEF cells were 
treated with either insulin at the indicated concentration or PMA at 1 μM for 10 mins.  Phospho-ERK (ERKP) and 
total ERK (ERKT) were then detected by Western blot.  B, WT MEF cells were treated with 100 nM insulin for the 
indicated times or PMA (1 μM) for 10 mins.  Cells were lysed for SDS PAGE.  ERKP and ERKT were then detected 
by Western blot.  C, WT MEF cells were treated with insulin at the indicated concentrations for 10 mins.  Cells were 
then fixed for ERKP staining.  D, WT, β1AR KO, β2AR KO, β1AR/β2AR DKO MEF cells were stimulated with 100 
nM insulin for 10 mins. Cells were lysed for SDS PAGE.  ERKP and ERKT were then detected by Western blot.  
ERKP was normalized against ERKT.  E, WT, β1AR KO, β2AR KO or βAR DKO cells were stimulated with either 
10 nM or 100 nM insulin for 10 mins. and fixed for ERKP staining.  F, WT MEF cells were transfected with a 
siRNA oligo targeting the mouse insulin receptor.  A scramble siRNA oligo was used as a negative control.  Cells 
were stimulated with 100 nM insulin for 10 mins.  Cells were then lysed and ERKP, ERKT and insulin receptor (IR) 
were then detected by Western blot.  ERKP was normalized against ERKT.  
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Figure 3.2. Cross talk with the β2AR is a significant pathway contributing to IR-induced ERK signaling A, 
H9C2 cardiac myoblasts were pretreated with either the AKT inhibitor LY294002 (LY; 10 μM, 10 mins.), Shc/Grb2 
inhibitor Actinomycin D (Actinomycin; 100 nM, 1h), MEK inhibitor U1026 (10 μM, 30 mins.) or the PKC 
stimulator PMA (1 μM, 10 mins.).  Cells were then stimulated with 100 nM insulin for 10 mins. Phospho-ERK 
(ERKP) and total ERK (ERKT) and phospho-AKT (AKTP) were then detected by Western blot.  ERKP was 
normalized against ERKT.  WT (B) or βAR DKO (C) MEF cells were pretreated, if indicated, with Actinomycin D 
(Actinomycin; 100 nM, 1h) and then stimulated with the indicated concentration of insulin for 10 mins.  ERKP and 
ERKT were then detected by Western blot. ERKP was normalized against ERKT.  D, WT or βAR DKO MEF cells 
were pretreated, if indicated, with Actinomycin D (Actinomycin; 100 nM, 1 hr.) and then stimulated with either 1 
nM or 100 nM for 10 mins.  Cells were then fixed for ERKP staining. 
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Figure 3.3. β2AR-dependent cytoplasmic sequestration of insulin-induced mitogenic signaling occurs via 
β2AR/β arrestin 2 scaffold formation A, WT, β arrestin 1 KO (βArr1 KO), β arrestin 2 KO (βArr2 KO) and β 
arrestin 1/β arrestin 2 DKO (βArr1/2 KO) MEF cells were stimulated with 100 nM insulin for 10 mins.  Phospho-
ERK (ERKP) and total ERK (ERKT) were detected by Western blot. ERKP was normalized against ERKT.  B, WT, β 
arrestin 1 KO or β arrestin 2 KO MEF cells were stimulated with 100 nM insulin for 10 mins. and fixed for ERKP 
staining. C, H9C2 cells were transfected for 48h with a mutant β arrestin 2 (V54D) that is incapable of internalizing 
the β2AR. Cells were then stimulated with 100 nM insulin for 10 mins.  ERKP and ERKT were then detected by 
Western blot. ERKP was normalized against ERKT.  D, H9C2 cardiac myoblasts expressing FLAG-β2AR together 
with GFP-β arrestin 2 were stimulated with 100 nM insulin for 10 mins.  Cells were lysed for immunoprecipitation 
with either an anti-β2AR (M2) or an anti-IRα antibody to examine the association between the β2AR/IR/β arrestin 2 
complex. E, H9C2 cardiac myoblasts expressing GFP-β arrestin 2 and FLAG-β2AR were stimulated with 100 nM 
insulin for 10 mins. before being fixed for either ERKP, β2AR or β arrestin 2 staining. 
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Figure 3.4. GRK2-mediated β2AR phosphorylation is required for insulin-induced ERK activity A, WT MEF 
cells were infected with lentiviruses expressing GRK-specific shRNA constructs for 72h with puromycin selection.  
Cells were then stimulated with 100 nM insulin for 10 mins.  Phospho-ERK (ERKP) and total ERK (ERKT) were 
then detected by Western blot. ERKP was normalized against ERKT.  B, β2AR KO MEF cells were transfected with 
WT β2AR or a β2AR with mutated GRK phosphorylation sites (GRK mut β2AR).  WT and β2AR KO MEF cells 
were then stimulated with 100 nM insulin for 10 mins.  ERKP, ERKT and total β2AR were then detected by Western 
blot. ERKP was normalized against ERKT.  H9C2 cardiac myoblast cells were infected with adenovirus expressing 
mouse β2AR and then stimulated with 100 nM insulin for the indicated times (C) or for 10 mins. at the indicated 
dose (D).  GRK-mediated phosphorylation of the β2AR at serines 355/356 was detected by Western blot.  355/356 
phosphorylation was normalized against total β2AR and represented as arbitrary units (AU).  E, H9C2 cells were 
infected with adenoviruses expressing either mouse β2AR and/or βARKct for 48h.  Cells were then stimulated with 
100 nM insulin for 10 mins. GRK-mediated phosphorylation of the β2AR at serines 355/356 in addition to total 
β2AR and GFP were detected by Western blot. Serines 355/356 phosphorylation was normalized against total β2AR 
and represented as arbitrary units (AU).  
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Figure 3.5. IRS2 recruits GRK2 to the insulin receptor allowing β2AR phosphorylation A, WT, insulin receptor 
substrate 1 knock out (IRS1 KO) or insulin receptor substrate 2 knock out (IRS2 KO) MEF cells were stimulated 
with 100 nM insulin for 10 mins.  Phospho-ERK (ERKP), total ERK (ERKT) and phospho-AKT (AKTP) were then 
detected by Western blot. ERKP was normalized against ERKT.  B, WT or IRS2 KO MEF cells were transfected 
with mouse β2AR and stimulated with 100 nM insulin for 10 mins.  GRK-mediated phosphorylation of the β2AR at 
serines 355/356 in addition to total β2AR was detected by Western blot. Serine 355/356 phosphorylation was 
normalized against total β2AR and represented as arbitrary units (AU).  C, WT MEF cells were lysed for 
immunoprecipitation with either an anti-IRS2 antibody or an anti-GRK2 antibody upon insulin stimulation (100 nM, 
10 mins.).  D, WT MEF cells were lysed for immunoprecipitation with an anti-insulin receptor α (IR) antibody upon 
100 nM insulin stimulation for 10 mins.  E, WT or IRS2 KO MEF cells were lysed for immunoprecipitation with an 
anti-IR antibody upon 100 nM insulin stimulation for 10 mins.  
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Figure 3.6. The C-terminal Pleckstrin Homology domain is essential in recruiting GRK2 to IRS2 A, WT MEF 
cells were transfected with plasmids expressing a polypeptide inhibitor of GRK2 (βARKct) lacking both the Kinase 
and N terminal RH domains, mutant GRK2 with a kinase domain mutation (∆ kinase), or a mutant GRK2 with an N 
terminal RGS homology domain deletion (∆ RH) for 48 hrs.  Mutants are represented in the adjacent model.  Cells 
were then stimulated with 100 nM insulin for 10 mins. in the presence or absence of these mutant GRK2 constructs.  
ERKP, ERKT and HA (∆ RH and ∆ Kinase) or GFP (βARKct) were then detected by Western blot. ERKP was 
normalized against ERKT.  B, WT MEF cells were transfected with either WT GRK2, a GFP-tagged βARKct 
construct, a HA-tagged ∆RH construct, or the ∆ Kinase mutant.  Cells were stimulated with 100 nM insulin for 10 
mins.  Cells were then lysed for immunoprecipitation with an anti-IRS2 antibody.  Proteins were resolved via SDS-
PAGE and blotted as indicated. 
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Figure 3.7. ERK activation upon cross talk with the β2AR is specific to type 2 RTKs WT or β2AR KO MEF 
cells were stimulated with insulin (100 nM, 10 mins.), insulin-like growth factor (IGF; 100 nM, 10 mins.), epidermal 
growth factor (EGF; 100 nM, 10 mins.), fibroblast growth factor (FGF; 100 nM, 10 mins.), platelet-derived growth 
factor (PDGF; 100 nM, 10 mins.) or nerve growth factor (NGF; 100 nM, 10 mins.).  Cells were then lysed and 
harvested for Western blot.  Phospho-ERK (ERKP) and total ERK (ERKT) were then detected by Western blot. 
ERKP was normalized against ERKT. 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. ERK dependent cell proliferation is insulin dose-dependent and is attenuated by the β2AR H9C2 
cells were pretreated with 1 μM of the MEK inhibitor U1026 (MEKi) for 30 mins.  Cells were then stimulated with 
10 nM insulin for 48 hrs. A, Cells were processed for quantitation of total protein concentration via BCA assay.  In 
addition, equal volumes of lysates were resolved via SDS-PAGE and blotted for γ-tubulin.  Alternatively, cells were 
either counted in a blinded manner (B), or BrdU incorporation was measured, and the data were normalized against 
the control (C).  WT, β1AR KO or β2AR KO MEF cells were stimulated with 100 nM insulin for 48h cells were then 
lysed and harvested.  Total protein concentration was measured via BCA assay (D).  Equal volumes of lysates were 
resolved via SDS-PAGE and blotted for γ tubulin. Alternatively, BrdU incorporation was measured, and the data 
were normalized against the control (E).  H9C2 cardiac myoblasts were treated for 48h with either 10 nM or 100 nM 
insulin and total protein concentration was quantitated via BCA assay (F).  Alternatively, cells were either counted 
in a blinded manner (G), or BrdU incorporation was measured, and the data were normalized against the control (H).  
In addition, cells were imaged 48 hrs. after 10 nM or 100 nM insulin treatment (I). 
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Figure 3.9. β2AR activation redistributes RTK-induced ERK to the cytoplasm and prevents cell proliferation 
A, H9C2 cardiac myoblasts were pretreated, if indicated, with 10 μM isoproterenol for 10 mins. and stimulated with 
10 nM insulin for 10 mins.  Cells were fixed for phospho-ERK  (ERKP) staining.  H9C2 cardiac myoblasts were 
preteated, if indicated, with isoproterenol (Iso, 10 μM, 10 mins.) and then stimulated for 48h with 10 nM insulin or 
10 μM of the α1AR agonist phenylephrine (Phe).  Total protein concentration was measured via BCA assay (B), 
cells were then counted in a blinded manner (C), and BrdU incorporation was measured, and the data were 
normalized against the control (D).  WT or β2AR KO MEF cells were pretreated, if indicated, for 10 mins. with 
isoproterenol (Iso) and then stimulated for 48h with 10 nM insulin.  Cells were then processed for quantitation of 
total protein concentration via BCA assay (E).  Alternatively, cells were counted in a blinded manner (F), or BrdU 
incorporation was measured, and the data were normalized against the control (G).  WT mouse embryonic stem cells 
were pretreated for 30 mins. with 10 μM isoproterenol, if indicated, and then stimulated for 24h with insulin (100 
nM) or insulin-like growth factor (IGF; 100 nM).  Total protein concentration was quantitated via BCA assay (H).  
Alternatively, BrdU incorporation was measured, and the data were normalized against the control (I). 
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Figure 3.10. Model of the mechanism on β2AR/β arrestin 2 complex mediated sequestration of insulin induced 
ERK activation At low concentrations of insulin (10 nM), ERK is activated via a classical IR/Shc/Grb2/SOS axis 
and translocates to the nucleus to promote cell proliferation.  Alternatively, activation of the insulin receptor (IR) 
with high concentrations (100 nM and above) of insulin induces IRS2-mediated GRK2 recruitment to the IR, which 
allows phosphorylation of the β2AR at serines 355/356.  GRK2-mediated β2AR phosphorylation leads to β arrestin 2 
recruitment and internalization of the β2AR.  Formation of this β2AR/β arrestin 2 signaling complex leads to ERK 
activation and is capable of sequestering phospho-ERK originating from the IR within the cytoplasm. 
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Supplementary Figure 3.I. βAR knock out alters ERK, but not AKT, signaling WT or β1AR/β2AR DKO (βAR 
DKO) MEF cells were stimulated with 100 nM insulin for 10 mins. phospho-ERK (ERKP), total ERK (ERKT) and 
phospho-AKT (AKTP) were detected via Western blot.   
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Supplementary Figure 3.II. IR cross talk occurs independently of classical β2AR signaling pathways H9C2 
cardiac myoblast cells were pretreated with either the PKA inhibitor H89 (10 μM, 30 mins.), the Gi inhibitor 
pertussis toxin (PTX; 200 nM, O/N), the PLC inhibitor U73122 (1 μM, 30 mins.), the PKC inhibitor calphostin C 
(Calp C; 10 μM, 30 mins.), the MEK inhibitor U1026 (10 μM, 30 mins.), or the PKC stimulator PMA (1 μM, 10 
mins.).  Cells were stimulated with 100 nM insulin for 10 mins.  Cells were then lysed and phospho-ERK (ERKP) 
and Total ERK (ERKT) were then detected by Western blot.  ERKP was normalized against ERKT. 
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Supplementary Figure 3.III. Protein expression not altered in β2AR MEF cells WT and β2AR MEF cells were 
lysed and harvested for Western blot for the indicated proteins. 
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Supplementary Figure 3.IV. Successful knockdown of GRK isoforms in H9C2 cells H9C2 cells were infected 
with lentiviruses expressing the indicated GRK isoforms for 72h under puromycin selection.  Cells were then lysed 
and harvested for Western blotting for the indicated GRK isoforms. 
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Supplementary Figure 3.V. Gi proteins are not required for cross talk between IR and β2AR WT, Gi1 KO, Gi2 
KO and Gi3 KO MEF cells were stimulated with 100 nM insulin for 10 mins.  Cells were then lysed and phospho-
ERK (ERKP) and total ERK (ERKT) were then detected by Western blot were then detected by Western blot. ERKP 
was normalized against ERKT. 
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Supplementary Figure 3.VI.  β2AR stimulation attenuates IGF-mediated mESC proliferation  WT mouse 
embryonic stem cells were pretreated for 30 mins. with 10 μM isoproterenol, if indicated, and then stimulated for 
24h with insulin (100 nM) or insulin-like growth factor (IGF; 100 nM).  Images were taken after 24h. 
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Chapter 4: 
Conclusions and future directions 
 Understanding how cells integrate information from a variety of chemically diverse 
signals into complex, orchestrated responses such as cell proliferation, differentiation and 
apoptosis is an overarching goal of cell biology.  Adrenergic signaling within the heart represents 
essential signaling cascades regulating both cardiac performance as well as pathophysiological 
remodeling. Due to the complexities of hormonal signaling in vivo, it is essential to understand 
how concomitant activation of one signaling pathway can alter the physiologic outcome of 
another receptor’s signaling.  Here, I began characterize the cellular mechanism by which GPCR 
cross-talk regulates mitogen-activated protein kinase (MAPK) activation and defined how this 
regulation affects cellular proliferation.  I then determined the mechanism by which type II RTK 
activation at high concentrations of mitogen recruits non-traditional GPCR signaling components 
to fine-tune activation of MAPK signaling.  Lastly, I illustrated how this regulation affects 
cellular proliferation.  These studies not only underscore the critical role of signaling cross-talk 
in the complex regulation of receptor signaling via sub cellular localization of signaling 
components, but also provide novel mechanisms into the regulation of mitogenic signaling 
elicited by different receptors.  It is critical to understand the role of adrenergic receptor cross-
talk in cardiac remodeling.  With this understanding, more efficient pharmacologic agents may 
be developed to prevent the progression of this major health problem.  
 Although the β adrenergic receptors (ARs) are central to cardiac remodling within the 
heart, their primary role within the myocardium is regulation of heart rate and contractility.  
Moreover, the signaling pathways implicated in cardiac remodeling also are essential in 
controlling cadiac output.  In addition, preliminary data from our lab suggests that cross-talk with 
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the insulin receptors is capable of blunting βAR-induced increases in cardiac contractility.  The 
importance of adrenergic receptor cross talk in modulating cardiac performance remains an 
interesting, and physiologically relevant, topic for future research. 
  
